

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/25807> holds various files of this Leiden University dissertation

Author: Verhaart, Ingrid

Title: Optimising antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy

Issue Date: 2014-05-20

References

1. Moat SJ, Bradley DM, Salmon R, Clarke A, Hartley L (2013), *Newborn bloodspot screening for Duchenne Muscular Dystrophy: 21 years experience in Wales (UK)*. *Eur J Hum Genet*; 21: 1049-1053.
2. Mendell JR, Lloyd-Puryear M (2013), *Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy*. *Muscle Nerve*; 48: 21-26.
3. Moser H (1984), *Duchenne muscular dystrophy: pathogenetic aspects and genetic prevention*. *Hum Genet*; 66: 17-40.
4. Gowers WR (1895), *A manual of the nervous system*. 2nd ed. Philadelphia.
5. Emery AE (2002), *The muscular dystrophies*. *Lancet*; 359: 687-695.
6. Passamano L, Taglia A, Palladino A, Viggiano E, D'Ambrosio P, Scutifero M *et al.* (2012), *Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients*. *Acta Myol*; 31: 121-125.
7. Angelini C, Peterle E (2012), *Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy*. *Acta Myol*; 31: 9-15.
8. Politano L, Nigro G (2012), *Treatment of dystrophinopathic cardiomyopathy: review of the literature and personal results*. *Acta Myol*; 31: 24-30.
9. Alman BA, Raza SN, Biggar WD (2004), *Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy*. *J Bone Joint Surg Am*; 86-A: 519-524.
10. Angelini C (2007), *The role of corticosteroids in muscular dystrophy: a critical appraisal*. *Muscle Nerve*; 36: 424-435.
11. Barber BJ, Andrews JG, Lu Z, West NA, Meaney FJ, Price ET *et al.* (2013), *Oral corticosteroids and onset of cardiomyopathy in duchenne muscular dystrophy*. *J Pediatr*; 163: 1080-1084.
12. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L *et al.* (2010), *Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management*. *Lancet Neurol*; 9: 77-93.
13. Merlini L, Cicognani A, Malaspina E, Gennari M, Gnudi S, Talim B *et al.* (2003), *Early prednisone treatment in Duchenne muscular dystrophy*. *Muscle Nerve*; 27: 222-227.
14. Ishikawa Y, Bach JR, Minami R (1999), *Cardioprotection for Duchenne's muscular dystrophy*. *Am Heart J*; 137: 895-902.
15. Ramaciotti C, Heistein LC, Coursey M, Lemler MS, Eapen RS, Iannaccone ST *et al.* (2006), *Left ventricular function and response to enalapril in patients with duchenne muscular dystrophy during the second decade of life*. *Am J Cardiol*; 98: 825-827.
16. Rall S, Grimm T (2012), *Survival in Duchenne muscular dystrophy*. *Acta Myol*; 31: 117-120.
17. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K (2002), *Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation*. *Neuromuscul Disord*; 12: 926-929.
18. Eagle M, Bourke J, Bullock R, Gibson M, Mehta J, Giddings D *et al.* (2007), *Managing Duchenne muscular dystrophy--the additive effect of spinal surgery and home nocturnal ventilation in improving survival*. *Neuromuscul Disord*; 17: 470-475.
19. Yasuma F, Sakai M, Matsuoka Y (1996), *Effects of noninvasive ventilation on survival in patients with Duchenne's muscular dystrophy*. *Chest*; 109: 590.
20. Finsterer J, Stollberger C (2008), *Cardiac involvement in Becker muscular dystrophy*. *Can J Cardiol*; 24: 786-792.
21. Nigro G, Comi LI, Politano L, Limongelli FM, Nigro V, De Rimini ML *et al.* (1995), *Evaluation of the cardiomyopathy in Becker muscular dystrophy*. *Muscle Nerve*; 18: 283-291.
22. Hoogerwaard EM, Bakker E, Ippel PF, Oosterwijk JC, Majoor-Krakauer DF, Leschot NJ *et al.* (1999), *Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in The Netherlands: a cohort study*. *Lancet*; 353: 2116-2119.
23. Norman A, Harper P (1989), *A survey of manifesting carriers of Duchenne and Becker muscular dystrophy in Wales*. *Clin Genet*; 36: 31-37.
24. Schade van Westrum SM, Hoogerwaard EM, Dekker L, Standaar TS, Bakker E, Ippel PF *et al.* (2011), *Cardiac abnormalities in a follow-up study on carriers of Duchenne and Becker muscular dystrophy*. *Neurology*; 77: 62-66.
25. Grain L, Cortina-Borja M, Forfar C, Hilton-Jones D, Hopkin J, Burch M (2001), *Cardiac abnormalities and skeletal muscle weakness in carriers of Duchenne and Becker muscular dystrophies and controls*. *Neuromuscul Disord*; 11: 186-191.
26. Mercier S, Toutain A, Toussaint A, Raynaud M, de BC, Marcorelles P *et al.* (2013), *Genetic and clinical specificity of 26 symptomatic carriers for dystrophinopathies at pediatric age*. *Eur J Hum Genet*; 21: 855-863.

27. Viggiano E, Picillo E, Cirillo A, Politano L (2013), *Comparison of X-chromosome inactivation in Duchenne muscle/myocardium-manifesting carriers, non-manifesting carriers and related daughters*. Clin Genet; 84: 265-270.
28. Boyd Y, Buckle V, Holt S, Munro E, Hunter D, Craig I (1986), *Muscular dystrophy in girls with X;autosomal translocations*. J Med Genet; 23: 484-490.
29. Juan-Mateu J, Rodriguez MJ, Nascimento A, Jimenez-Mallebrera C, Gonzalez-Quereda L, Rivas E *et al.* (2012), *Prognostic value of X-chromosome inactivation in symptomatic female carriers of dystrophinopathy*. Orphanet J Rare Dis; 7: 82.
30. Burghes AH, Logan C, Hu X, Belfall B, Worton RG, Ray PN (1987), *A cDNA clone from the Duchenne/Becker muscular dystrophy gene*. Nature; 328: 434-437.
31. Davies KE, Pearson PL, Harper PS, Murray JM, O'Brien T, Sarfarazi M *et al.* (1983), *Linkage analysis of two cloned DNA sequences flanking the Duchenne muscular dystrophy locus on the short arm of the human X chromosome*. Nucleic Acids Res; 11: 2303-2312.
32. Jacobs PA, Hunt PA, Mayer M, Bart RD (1981), *Duchenne muscular dystrophy (DMD) in a female with an X/autosomal translocation: further evidence that the DMD locus is at Xp21*. Am J Hum Genet; 33: 513-518.
33. Monaco AP, Bertelson CJ, Middlesworth W, Colletti CA, Aldridge J, Fischbeck KH *et al.* (1985), *Detection of deletions spanning the Duchenne muscular dystrophy locus using a tightly linked DNA segment*. Nature; 316: 842-845.
34. Murray JM, Davies KE, Harper PS, Meredith L, Mueller CR, Williamson R (1982), *Linkage relationship of a cloned DNA sequence on the short arm of the X chromosome to Duchenne muscular dystrophy*. Nature; 300: 69-71.
35. van Ommen GJ, Verkerk JM, Hofker MH, Monaco AP, Kunkel LM, Ray P *et al.* (1986), *A physical map of 4 million bp around the Duchenne muscular dystrophy gene on the human X-chromosome*. Cell; 47: 499-504.
36. Kingston HM, Sarfarazi M, Thomas NS, Harper PS (1984), *Localisation of the Becker muscular dystrophy gene on the short arm of the X chromosome by linkage to cloned DNA sequences*. Hum Genet; 67: 6-17.
37. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM (1987), *Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals*. Cell; 50: 509-517.
38. den Dunnen JT, Bakker E, Breteler EG, Pearson PL, van Ommen GJ (1987), *Direct detection of more than 50% of the Duchenne muscular dystrophy mutations by field inversion gels*. Nature; 329: 640-642.
39. Hoffman EP, Brown Jr. RH, Kunkel LM (1987), *Dystrophin: the protein product of the Duchenne muscular dystrophy locus*. Cell; 51: 919-928.
40. Hoffman EP, Kunkel LM, Angelini C, Clarke A, Johnson M, Harris JB (1989), *Improved diagnosis of Becker muscular dystrophy by dystrophin testing*. Neurology; 39: 1011-1017.
41. Hoffman EP, Fischbeck KH, Brown RH, Johnson M, Medori R, Loike JD *et al.* (1988), *Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy*. N Engl J Med; 318: 1363-1368.
42. Koenig M, Beggs AH, Moyer M, Scherpf S, Heindrich K, Bettecken T *et al.* (1989), *The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion*. Am J Hum Genet; 45: 498-506.
43. Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM (1988), *An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus*. Genomics; 2: 90-95.
44. Aartsma-Rus A, van Deutekom JC, Fokkema IF, van Ommen GJ, den Dunnen JT (2006), *Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule*. Muscle Nerve; 34: 135-144.
45. Roberts RG, Coffey AJ, Bobrow M, Bentley DR (1993), *Exon structure of the human dystrophin gene*. Genomics; 16: 536-538.
46. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J *et al.* (2001), *Initial sequencing and analysis of the human genome*. Nature; 409: 860-921.
47. Laing NG (1993), *Molecular genetics and genetic counselling for Duchenne/Becker muscular dystrophy*. Mol Cell Biol Hum Dis Ser; 3: 37-84.
48. den Dunnen JT, Bakker E, van Ommen GJ, Pearson PL (1989), *The DMD gene analysed by field inversion gel electrophoresis*. Br Med Bull; 45: 644-658.
49. Muntoni F, Torelli S, Ferlini A (2003), *Dystrophin and mutations: one gene, several proteins, multiple phenotypes*. Lancet Neurol; 2: 731-740.
50. Neri M, Torelli S, Brown S, Ugo I, Sabatelli P, Merlini L *et al.* (2007), *Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human*. Neuromuscul Disord; 17: 913-918.
51. Anthony K, Cirak S, Torelli S, Tasca G, Feng L, Arechavala-Gomez V *et al.* (2011), *Dystrophin quantifi-*

- cation and clinical correlations in Becker muscular dystrophy: implications for clinical trials.* Brain; 134: 3547-3559.
52. Bushby KM, Gardner-Medwin D, Nicholson LV, Johnson MA, Haggerty ID, Cleghorn NJ *et al.* (1993), *The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. II. Correlation of phenotype with genetic and protein abnormalities.* J Neurol; 240: 105-112.
 53. Comi GP, Prella A, Bresolin N, Moggio M, Bardoni A, Gallanti A *et al.* (1994), *Clinical variability in Becker muscular dystrophy. Genetic, biochemical and immunohistochemical correlates.* Brain; 117 (Pt 1): 1-14.
 54. Beggs AH, Hoffman EP, Snyder JR, Arahata K, Specht L, Shapiro F *et al.* (1991), *Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies.* Am J Hum Genet; 49: 54-67.
 55. Amann KJ, Renley BA, Ervasti JM (1998), *A cluster of basic repeats in the dystrophin rod domain binds F-actin through an electrostatic interaction.* J Biol Chem; 273: 28419-28423.
 56. Lai Y, Thomas GD, Yue Y, Yang HT, Li D, Long C *et al.* (2009), *Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy.* J Clin Invest; 119: 624-635.
 57. Ehmsen J, Poon E, Davies K (2002), *The dystrophin-associated protein complex.* J Cell Sci; 115: 2801-2803.
 58. Gumerson JD, Michele DE (2011), *The dystrophin-glycoprotein complex in the prevention of muscle damage.* J Biomed Biotechnol; 2011: 210797.
 59. Bellinger AM, Reiken S, Carlson C, Mongillo M, Liu X, Rothman L *et al.* (2009), *Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle.* Nat Med; 15: 325-330.
 60. Miller G, Wang EL, Nassar KL, Peter AK, Crosbie RH (2007), *Structural and functional analysis of the sarcoglycan-sarcospan subcomplex.* Exp Cell Res; 313: 639-651.
 61. Hezel M, de Groat WC, Galbiati F (2010), *Caveolin-3 promotes nicotinic acetylcholine receptor clustering and regulates neuromuscular junction activity.* Mol Biol Cell; 21: 302-310.
 62. Brenman JE, Chao DS, Xia H, Aldape K, Brecht DS (1995), *Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy.* Cell; 82: 743-752.
 63. Gee SH, Madhavan R, Levinson SR, Caldwell JH, Sealock R, Froehner SC (1998), *Interaction of muscle and brain sodium channels with multiple members of the syntrophin family of dystrophin-associated proteins.* J Neurosci; 18: 128-137.
 64. Newey SE, Howman EV, Ponting CP, Benson MA, Nawrotzki R, Loh NY *et al.* (2001), *Syncoilin, a novel member of the intermediate filament superfamily that interacts with alpha-dystrobrevin in skeletal muscle.* J Biol Chem; 276: 6645-6655.
 65. Nicolas A, Lucchetti-Miganeh C, Yaou RB, Kaplan JC, Chelly J, Leturcq F *et al.* (2012), *Assessment of the structural and functional impact of in-frame mutations of the DMD gene, using the tools included in the eDystrophin online database.* Orphanet J Rare Dis; 7: 45.
 66. Chelly J, Hamard G, Koulakoff A, Kaplan JC, Kahn A, Berwald-Netter Y (1990), *Dystrophin gene transcribed from different promoters in neuronal and glial cells.* Nature; 344: 64-65.
 67. Gorecki DC, Monaco AP, Derry JM, Walker AP, Barnard EA, Barnard PJ (1992), *Expression of four alternative dystrophin transcripts in brain regions regulated by different promoters.* Hum Mol Genet; 1: 505-510.
 68. D'Souza VN, Nguyen TM, Morris GE, Karges W, Pillers DA, Ray PN (1995), *A novel dystrophin isoform is required for normal retinal electrophysiology.* Hum Mol Genet; 4: 837-842.
 69. Byers TJ, Lidov HG, Kunkel LM (1993), *An alternative dystrophin transcript specific to peripheral nerve.* Nat Genet; 4: 77-81.
 70. Hugnot JP, Gilgenkrantz H, Vincent N, Chafey P, Morris GE, Monaco AP *et al.* (1992), *Distal transcript of the dystrophin gene initiated from an alternative first exon and encoding a 75-kDa protein widely distributed in nonmuscle tissues.* Proc Natl Acad Sci USA; 89: 7506-7510.
 71. Tadayoni R, Rendon A, Soria-Jasso LE, Cisneros B (2012), *Dystrophin Dp71: the smallest but multifunctional product of the Duchenne muscular dystrophy gene.* Mol Neurobiol; 45: 43-60.
 72. Snow WM, Anderson JE, Jakobson LS (2013), *Neuropsychological and neurobehavioral functioning in Duchenne muscular dystrophy: a review.* Neurosci Biobehav Rev; 37: 743-752.
 73. Waite A, Brown SC, Blake DJ (2012), *The dystrophin-glycoprotein complex in brain development and disease.* Trends Neurosci; 35: 487-496.
 74. Taylor PJ, Betts GA, Maroulis S, Gilissen C, Pedersen RL, Mowat DR *et al.* (2010), *Dystrophin gene mutation location and the risk of cognitive impairment in Duchenne muscular dystrophy.* PLoS One; 5: e8803.
 75. Tinsley JM, Blake DJ, Davies KE (1993), *Apo-dystrophin-3: a 2.2kb transcript from the DMD locus encoding the dystrophin glycoprotein binding site.* Hum Mol Genet; 2: 521-524.

76. Tozawa T, Itoh K, Yaoi T, Tando S, Umekage M, Dai H *et al.* (2012), *The shortest isoform of dystrophin (Dp40) interacts with a group of presynaptic proteins to form a presumptive novel complex in the mouse brain.* Mol Neurobiol; 45: 287-297.
77. Moizard MP, Billard C, Toutain A, Berret F, Marmin N, Moraine C (1998), *Are Dp71 and Dp140 brain dystrophin isoforms related to cognitive impairment in Duchenne muscular dystrophy?* Am J Med Genet; 80: 32-41.
78. Pillers DA, Fitzgerald KM, Duncan NM, Rash SM, White RA, Dwinell SJ *et al.* (1999), *Duchenne/Becker muscular dystrophy: correlation of phenotype by electroretinography with sites of dystrophin mutations.* Hum Genet; 105: 2-9.
79. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, Barnard PJ (1989), *The molecular basis of muscular dystrophy in the mdx mouse: a point mutation.* Science; 244: 1578-1580.
80. Verhaart IE, van Duijn RJ, den Adel B, Roest AA, Verschuuren JJ, Aartsma-Rus A *et al.* (2012), *Assessment of cardiac function in three mouse dystrophinopathies by magnetic resonance imaging.* Neuromuscul Disord; 22: 418-426.
81. Chamberlain JS, Metzger J, Reyes M, Townsend D, Faulkner JA (2007), *Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma.* FASEB J; 21: 2195-2204.
82. Khurana TS, Watkins SC, Chafey P, Chelly J, Tome FM, Fardeau M *et al.* (1991), *Immunolocalization and developmental expression of dystrophin related protein in skeletal muscle.* Neuromuscul Disord; 1: 185-194.
83. Khurana TS, Davies KE (2003), *Pharmacological strategies for muscular dystrophy.* Nat Rev Drug Discov; 2: 379-390.
84. Tinsley JM, Blake DJ, Roche A, Fairbrother U, Riss J, Byth BC *et al.* (1992), *Primary structure of dystrophin-related protein.* Nature; 360: 591-593.
85. Mizuno Y, Nonaka I, Hirai S, Ozawa E (1993), *Reciprocal expression of dystrophin and utrophin in muscles of Duchenne muscular dystrophy patients, female DMD-carriers and control subjects.* J Neurol Sci; 119: 43-52.
86. Deconinck AE, Rafael JA, Skinner JA, Brown SC, Potter AC, Metzinger L *et al.* (1997), *Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy.* Cell; 90: 717-727.
87. Zhou L, Rafael-Fortney JA, Huang P, Zhao XS, Cheng G, Zhou X *et al.* (2008), *Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx mice.* J Neurol Sci; 264: 106-111.
88. van Putten M, Kumar D, Hulsker M, Hoogaars WM, Plomp JJ, van Opstal A. *et al.* (2012), *Comparison of skeletal muscle pathology and motor function of dystrophin and utrophin deficient mouse strains.* Neuromuscul Disord; 22: 406-417.
89. Willmann R, Possekel S, Dubach-Powell J, Meier T, Ruegg MA (2009), *Mammalian animal models for Duchenne muscular dystrophy.* Neuromuscul Disord; 19: 241-249.
90. Durbeek M, Campbell KP (2002), *Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models.* Curr Opin Genet Dev; 12: 349-361.
91. Megeney LA, Kablar B, Garrett K, Anderson JE, Rudnicki MA (1996), *MyoD is required for myogenic stem cell function in adult skeletal muscle.* Genes Dev; 10: 1173-1183.
92. Garry DJ, Meeson A, Elterman J, Zhao Y, Yang P, Bassel-Duby R *et al.* (2000), *Myogenic stem cell function is impaired in mice lacking the forkhead/winged helix protein MNF.* Proc Natl Acad Sci USA; 97: 5416-5421.
93. Grady RM, Grange RW, Lau KS, Maimone MM, Nichol MC, Stull JT *et al.* (1999), *Role for alpha-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies.* Nat Cell Biol; 1: 215-220.
94. Guo C, Willem M, Werner A, Raivich G, Emerson M, Neyses L *et al.* (2006), *Absence of alpha 7 integrin in dystrophin-deficient mice causes a myopathy similar to Duchenne muscular dystrophy.* Hum Mol Genet; 15: 989-998.
95. Raymackers JM, Debaix H, Colson-Van SM, De BF, Tajeddine N, Schwaller B *et al.* (2003), *Consequence of parvalbumin deficiency in the mdx mouse: histological, biochemical and mechanical phenotype of a new double mutant.* Neuromuscul Disord; 13: 376-387.
96. Crosbie RH, Straub V, Yun HY, Lee JC, Rafael JA, Chamberlain JS *et al.* (1998), *Mdx muscle pathology is independent of nNOS perturbation.* Hum Mol Genet; 7: 823-829.
97. Fukada S, Morikawa D, Yamamoto Y, Yoshida T, Sumie N, Yamaguchi M *et al.* (2010), *Genetic background affects properties of satellite cells and mdx phenotypes.* Am J Pathol; 176: 2414-2424.
98. Chapman VM, Miller DR, Armstrong D, Caskey CT (1989), *Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice.* Proc Natl Acad Sci USA; 86: 1292-1296.
99. Im WB, Phelps SF, Copen EH, Adams EG, Slightom JL, Chamberlain JS (1996), *Differential expression of dystrophin isoforms in strains of mdx mice with different mutations.* Hum Mol Genet; 5: 1149-1153.

100. Cox GA, Phelps SF, Chapman VM, Chamberlain JS (1993), *New mdx mutation disrupts expression of muscle and nonmuscle isoforms of dystrophin*. *Nat Genet*; 4: 87-93.
101. Danko I, Chapman V, Wolff JA (1992), *The frequency of revertants in mdx mouse genetic models for Duchenne muscular dystrophy*. *Pediatr Res*; 32: 128-131.
102. Li D, Yue Y, Duan D (2008), *Preservation of muscle force in Mdx3cv mice correlates with low-level expression of a near full-length dystrophin protein*. *Am J Pathol*; 172: 1332-1341.
103. Beastro N, Lu H, Macke A, Canan BD, Johnson EK, Penton CM *et al.* (2011), *Mdx((5)cv) mice manifest more severe muscle dysfunction and diaphragm force deficits than do mdx mice*. *Am J Pathol*; 179: 2464-2474.
104. Morrison J, Lu QL, Pastoret C, Partridge T, Bou-Gharios G (2000), *T-cell-dependent fibrosis in the mdx dystrophic mouse*. *Lab Invest*; 80: 881-891.
105. Morrison J, Partridge T, Bou-Gharios G (2005), *Nude mutation influences limb skeletal muscle development*. *Matrix Biol*; 23: 535-542.
106. Bosma GC, Custer RP, Bosma MJ (1983), *A severe combined immunodeficiency mutation in the mouse*. *Nature*; 301: 527-530.
107. Torrente Y, Belicchi M, Sampaolesi M, Pisati F, Meregalli M, D'Antona G *et al.* (2004), *Human circulating AC133(+) stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle*. *J Clin Invest*; 114: 182-195.
108. Arpke RW, Darabi R, Mader TL, Zhang Y, Toyama A, Lonetree CL *et al.* (2013), *A new immuno-, dystrophin-deficient model, the NSG-mdx(4Cv) mouse, provides evidence for functional improvement following allogeneic satellite cell transplantation*. *Stem Cells*; 31: 1611-1620.
109. Araki E, Nakamura K, Nakao K, Kameya S, Kobayashi O, Nonaka I *et al.* (1997), *Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy*. *Biochem Biophys Res Commun*; 238: 492-497.
110. Sarig R, Mezger-Lallemand V, Gitelman I, Davis C, Fuchs O, Yaffe D *et al.* (1999), *Targeted inactivation of Dp71, the major non-muscle product of the DMD gene: differential activity of the Dp71 promoter during development*. *Hum Mol Genet*; 8: 1-10.
111. Cox GA, Cole NM, Matsumura K, Phelps SF, Hauschka SD, Campbell KP *et al.* (1993), *Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity*. *Nature*; 364: 725-729.
112. Cox GA, Sunada Y, Campbell KP, Chamberlain JS (1994), *Dp71 can restore the dystrophin-associated glycoprotein complex in muscle but fails to prevent dystrophy*. *Nat Genet*; 8: 333-339.
113. Greenberg DS, Sunada Y, Campbell KP, Yaffe D, Nudel U (1994), *Exogenous Dp71 restores the levels of dystrophin associated proteins but does not alleviate muscle damage in mdx mice*. *Nat Genet*; 8: 340-344.
114. Rafael JA, Sunada Y, Cole NM, Campbell KP, Faulkner JA, Chamberlain JS (1994), *Prevention of dystrophic pathology in mdx mice by a truncated dystrophin isoform*. *Hum Mol Genet*; 3: 1725-1733.
115. Banks GB, Gregorevic P, Allen JM, Finn EE, Chamberlain JS (2007), *Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domain*. *Hum Mol Genet*; 16: 2105-2113.
116. Phelps SF, Hauser MA, Cole NM, Rafael JA, Hinkle RT, Faulkner JA *et al.* (1995), *Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice*. *Hum Mol Genet*; 4: 1251-1258.
117. Dunant P, Larochelle N, Thirion C, Stucka R, Ursu D, Petrof BJ *et al.* (2003), *Expression of dystrophin driven by the 1.35-kb MCK promoter ameliorates muscular dystrophy in fast, but not in slow muscles of transgenic mdx mice*. *Mol Ther*; 8: 80-89.
118. Stillwell E, Vitale J, Zhao Q, Beck A, Schneider J, Khadim F *et al.* (2009), *Blastocyst injection of wild type embryonic stem cells induces global corrections in mdx mice*. *PLoS One*; 4: e4759.
119. van Putten M, Hulsker M, Nadarajah VD, van Heiningen SH, van Huizen E, van Iterson M. *et al.* (2012), *The effects of low levels of dystrophin on mouse muscle function and pathology*. *PLoS One*; 7: e31937.
120. van Putten M, Hulsker M, Young C, Nadarajah VD, Heemskerck H, van der Weerd L *et al.* (2013), *Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice*. *FASEB J*; 27: 2484-2495.
121. 't Hoen PA, de Meijer EJ, Boer JM, Vossen RH, Turk R, Maatman RG *et al.* (2008), *Generation and characterization of transgenic mice with the full-length human DMD gene*. *J Biol Chem*; 283: 5899-5907.
122. Sharp NJ, Kornegay JN, Van Camp SD, Herbstreith MH, Secore SL, Kettle S *et al.* (1992), *An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy*. *Genomics*; 13: 115-121.
123. Howell JM, Fletcher S, Kakulas BA, O'Hara M, Lochmuller H, Karpati G (1997), *Use of the dog model for Duchenne muscular dystrophy in gene therapy trials*. *Neuromuscul Disord*; 7: 325-328.
124. Ambrosio CE, Valadares MC, Zucconi E, Cabral R, Pearson PL, Gaiad TP *et al.* (2008), *Ringo, a Golden Retriever Muscular Dystrophy (GRMD) dog with absent dystrophin but normal strength*. *Neuromuscul Disord*; 18: 892-893.

125. Valentine BA, Winand NJ, Pradhan D, Moise NS, de LA, Kornegay JN *et al.* (1992), *Canine X-linked muscular dystrophy as an animal model of Duchenne muscular dystrophy: a review*. Am J Med Genet; 42: 352-356.
126. Shimatsu Y, Yoshimura M, Yuasa K, Urasawa N, Tomohiro M, Nakura M *et al.* (2005), *Major clinical and histopathological characteristics of canine X-linked muscular dystrophy in Japan, CXMDJ*. Acta Myol; 24: 145-154.
127. Yugeta N, Urasawa N, Fujii Y, Yoshimura M, Yuasa K, Wada MR *et al.* (2006), *Cardiac involvement in Beagle-based canine X-linked muscular dystrophy in Japan (CXMDJ): electrocardiographic, echocardiographic, and morphologic studies*. BMC Cardiovasc Disord; 6: 47.
128. Shimatsu Y, Katagiri K, Furuta T, Nakura M, Tanioka Y, Yuasa K *et al.* (2003), *Canine X-linked muscular dystrophy in Japan (CXMDJ)*. Exp Anim; 52: 93-97.
129. Schatzberg SJ, Olby NJ, Breen M, Anderson LV, Langford CF, Dickens HF *et al.* (1999), *Molecular analysis of a spontaneous dystrophin 'knockout' dog*. Neuromuscul Disord; 9: 289-295.
130. Walmsley GL, Arechavala-Gomez V, Fernandez-Fuente M, Burke MM, Nagel N, Holder A *et al.* (2010), *A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping*. PLoS One; 5: e8647.
131. Bergman RL, Inzana KD, Monroe WE, Shell LG, Liu LA, Engvall E *et al.* (2002), *Dystrophin-deficient muscular dystrophy in a Labrador retriever*. J Am Anim Hosp Assoc; 38: 255-261.
132. Van Ham LML, Desmidt M, Tshamata M. (1993), *Canine X linked muscular dystrophy in Belgian Groenendaeler Shepherds*. J Am Anim Hosp Assoc; 570-574.
133. Van Ham LML, Roels S, Hoorens J.K. (1995), *Congenital dystrophy-like myopathy in a Brittany spaniel puppy*. Prog Vet Neurol; 135-138.
134. Wentick GH, Vanderlinde-Sipman JS, Meijer AEFH (1972), *Myopathy with a possible recessive x-linked inheritance in a litter of Irish terriers*. Vet Pathol; 328-349.
135. Paola JP, Podell M, Shelton GD (1993), *Muscular dystrophy in a miniature Schnauzer*. Prog Vet Neurol; 14-18.
136. Wetterman CA, Harkin KR, Cash WC, Nietfield JC, Shelton GD (2000), *Hypertrophic muscular dystrophy in a young dog*. J Am Vet Med Assoc; 216: 878-81, 864.
137. Jones BR, Brennan S, Mooney CT, Callanan JJ, McAllister H, Guo LT *et al.* (2004), *Muscular dystrophy with truncated dystrophin in a family of Japanese Spitz dogs*. J Neurol Sci; 217: 143-149.
138. Carpenter JL, Hoffman EP, Romanul FC, Kunkel LM, Rosales RK, Ma NS *et al.* (1989), *Feline muscular dystrophy with dystrophin deficiency*. Am J Pathol; 135: 909-919.
139. Winand NJ, Edwards M, Pradhan D, Berian CA, Cooper BJ (1994), *Deletion of the dystrophin muscle promoter in feline muscular dystrophy*. Neuromuscul Disord; 4: 433-445.
140. Gaschen FP, Hoffman EP, Gorospe JR, Uhl EW, Senior DF, Cardinet GH, III *et al.* (1992), *Dystrophin deficiency causes lethal muscle hypertrophy in cats*. J Neurol Sci; 110: 149-159.
141. Gaschen L, Lang J, Lin S, Ade-Damilano M, Busato A, Lombard CW *et al.* (1999), *Cardiomyopathy in dystrophin-deficient hypertrophic feline muscular dystrophy*. J Vet Intern Med; 13: 346-356.
142. Roberts RG, Bobrow M (1998), *Dystrophins in vertebrates and invertebrates*. Hum Mol Genet; 7: 589-595.
143. Bessou C, Giuglia JB, Franks CJ, Holden-Dye L, Segalat L (1998), *Mutations in the Caenorhabditis elegans dystrophin-like gene dys-1 lead to hyperactivity and suggest a link with cholinergic transmission*. Neurogenetics; 2: 61-72.
144. Gieseler K, Grisoni K, Segalat L (2000), *Genetic suppression of phenotypes arising from mutations in dystrophin-related genes in Caenorhabditis elegans*. Curr Biol; 10: 1092-1097.
145. Bassett DI, Currie PD (2003), *The zebrafish as a model for muscular dystrophy and congenital myopathy*. Hum Mol Genet; 12 Spec No 2: R265-R270.
146. Guyon JR, Goswami J, Jun SJ, Thorne M, Howell M, Pusack T *et al.* (2009), *Genetic isolation and characterization of a splicing mutant of zebrafish dystrophin*. Hum Mol Genet; 18: 202-211.
147. Klymiuk N, Blutke A, Graf A, Krause S, Burkhardt K, Wuensch A *et al.* (2013), *Dystrophin-deficient pigs provide new insights into the hierarchy of physiological derangements of dystrophic muscle*. Hum Mol Genet; 22: 4368-4382.
148. Aigner B, Renner S, Kessler B, Klymiuk N, Kurome M, Wunsch A *et al.* (2010), *Transgenic pigs as models for translational biomedical research*. J Mol Med (Berl); 88: 653-664.
149. Baker BF, Monia BP (1999), *Novel mechanisms for antisense-mediated regulation of gene expression*. Biochim Biophys Acta; 1489: 3-18.
150. Chan JH, Lim S, Wong WS (2006), *Antisense oligonucleotides: from design to therapeutic application*. Clin Exp Pharmacol Physiol; 33: 533-540.
151. Sproat BS, Lamond AI, Beijer B, Neuner P, Ryder U (1989), *Highly efficient chemical synthesis of 2'-O-methyllogribonucleotides and tetrabiotinylated derivatives; novel probes that are resistant to deg-*

- radation by RNA or DNA specific nucleases. *Nucleic Acids Res*; 17: 3373-3386.
152. van Ommen GJ, van DJ, Aartsma-Rus A (2008), *The therapeutic potential of antisense-mediated exon skipping*. *Curr Opin Mol Ther*; 10: 140-149.
153. Watanabe TA, Geary RS, Levin AA (2006), *Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302)*. *Oligonucleotides*; 16: 169-180.
154. Larsen HJ, Bentin T, Nielsen PE (1999), *Antisense properties of peptide nucleic acid*. *Biochim Biophys Acta*; 1489: 159-166.
155. Aartsma-Rus A, Kaman WE, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ *et al.* (2004), *Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells*. *Gene Ther*; 11: 1391-1398.
156. Fabani MM, Gait MJ (2008), *miR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates*. *RNA*; 14: 336-346.
157. Morita K, Hasegawa C, Kaneko M, Tsutsumi S, Sone J, Ishikawa T *et al.* (2002), *2'-O,4'-C-ethylene-bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug*. *Bioorg Med Chem Lett*; 12: 73-76.
158. Yagi M, Takeshima Y, Surono A, Takagi M, Koizumi M, Matsuo M (2004), *Chimeric RNA and 2'-O, 4'-C-ethylene-bridged nucleic acids have stronger activity than phosphorothioate oligodeoxynucleotides in induction of exon 19 skipping in dystrophin mRNA*. *Oligonucleotides*; 14: 33-40.
159. Geary RS, Watanabe TA, Truong L, Freier S, Lesnik EA, Sioufi NB *et al.* (2001), *Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats*. *J Pharmacol Exp Ther*; 296: 890-897.
160. Oberbauer R, Schreiner GF, Meyer TW (1995), *Renal uptake of an 18-mer phosphorothioate oligonucleotide*. *Kidney Int*; 48: 1226-1232.
161. Heemskerk HA, de Winter CL, de Kimpse SJ, van Kuik-Romeijn P, Heuvelmans N, Platenburg GJ *et al.* (2009), *In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping*. *J Gene Med*; 11: 257-266.
162. Moulton HM, Moulton JD (2010), *Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy*. *Biochim Biophys Acta*; 1798: 2296-2303.
163. Wu B, Li Y, Morcos PA, Doran TJ, Lu P, Lu QL (2009), *Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice*. *Mol Ther*; 17: 864-871.
164. Aartsma-Rus A, van Vliet L, Hirschi M, Janson AA, Heemskerk H, de Winter CL *et al.* (2009), *Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms*. *Mol Ther*; 17: 548-553.
165. Kole R, Williams T, Cohen L (2004), *RNA modulation, repair and remodeling by splice switching oligonucleotides*. *Acta Biochim Pol*; 51: 373-378.
166. Tanaka K, Watakabe A, Shimura Y (1994), *Polypurine sequences within a downstream exon function as a splicing enhancer*. *Mol Cell Biol*; 14: 1347-1354.
167. Aartsma-Rus A, de Winter CL, Janson AA, Kaman WE, van Ommen GJ, den Dunnen JT *et al.* (2005), *Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites*. *Oligonucleotides*; 15: 284-297.
168. Matsuo M, Masumura T, Nakajima T, Kitoh Y, Takumi T, Nishio H *et al.* (1990), *A very small frame-shifting deletion within exon 19 of the Duchenne muscular dystrophy gene*. *Biochem Biophys Res Commun*; 170: 963-967.
169. Matsuo M, Masumura T, Nishio H, Nakajima T, Kitoh Y, Takumi T *et al.* (1991), *Exon skipping during splicing of dystrophin mRNA precursor due to an intraexon deletion in the dystrophin gene of Duchenne muscular dystrophy Kobe*. *J Clin Invest*; 87: 2127-2131.
170. Pramono ZA, Takeshima Y, Alimsardjono H, Ishii A, Takeda S, Matsuo M (1996), *Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence*. *Biochem Biophys Res Commun*; 226: 445-449.
171. Takeshima Y, Nishio H, Sakamoto H, Nakamura H, Matsuo M (1995), *Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe*. *J Clin Invest*; 95: 515-520.
172. Takeshima Y, Wada H, Yagi M, Ishikawa Y, Ishikawa Y, Minami R *et al.* (2001), *Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient*. *Brain Dev*; 23: 788-790.
173. van Deutekom JC, Bremmer-Bout M, Janson AA, Ginjaar IB, Baas F, den Dunnen JT *et al.* (2001), *Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells*. *Hum Mol Genet*; 10: 1547-1554.

174. Dunckley MG, Manoharan M, Villiet P, Eperon IC, Dickson G (1998), *Modification of splicing in the dystrophin gene in cultured mdx muscle cells by antisense oligoribonucleotides*. Hum Mol Genet; 7: 1083-1090.
175. Wilton SD, Lloyd F, Carville K, Fletcher S, Honeyman K, Agrawal S *et al.* (1999), *Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides*. Neuromuscul Disord; 9: 330-338.
176. Aartsma-Rus A, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ, van Deutekom JC (2002), *Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy*. Neuromuscul Disord; 12 Suppl 1:S71-7.: S71-S77.
177. Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, den Dunnen JT, Baas F *et al.* (2003), *Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients*. Hum Mol Genet; 12: 907-914.
178. Aartsma-Rus A, Janson AA, van Ommen GJ, van Deutekom JC (2007), *Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy*. BMC Med Genet; 8: 43.
179. Gurvich OL, Tuohy TM, Howard MT, Finkel RS, Medne L, Anderson CB *et al.* (2008), *DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy*. Ann Neurol; 63: 81-89.
180. Spitali P, Rimessi P, Fabris M, Perrone D, Falzarano S, Bovolenta M *et al.* (2009), *Exon skipping-mediated dystrophin reading frame restoration for small mutations*. Hum Mutat; 30: 1527-1534.
181. Yang L, Niu H, Gao X, Wang Q, Han G, Cao L *et al.* (2013), *Effective exon skipping and dystrophin restoration by 2'-O-methoxyethyl antisense oligonucleotide in dystrophin-deficient mice*. PLoS One; 8: e61584.
182. GebSKI BL, Mann CJ, Fletcher S, Wilton SD (2003), *Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle*. Hum Mol Genet; 12: 1801-1811.
183. Arechavala-Gomez V, Graham IR, Popplewell LJ, Adams AM, Aartsma-Rus A, Kinali M *et al.* (2007), *Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle*. Hum Gene Ther; 18: 798-810.
184. Popplewell LJ, Adkin C, Arechavala-Gomez V, Aartsma-Rus A, de Winter CL, Wilton SD *et al.* (2010), *Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials*. Neuromuscul Disord; 20: 102-110.
185. Takagi M, Yagi M, Ishibashi K, Takeshima Y, Surono A, Matsuo M *et al.* (2004), *Design of 2'-O-Me RNA/ENA chimera oligonucleotides to induce exon skipping in dystrophin pre-mRNA*. Nucleic Acids Symp Ser (Oxf); 297-298.
186. Yin H, Lu Q, Wood M (2008), *Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice*. Mol Ther; 16: 38-45.
187. Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen GJ *et al.* (2009), *Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations*. Hum Mutat; 30: 293-299.
188. Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, van Ommen GJ, den Dunnen JT *et al.* (2004), *Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense*. Am J Hum Genet; 74: 83-92.
189. McClorey G, Moulton HM, Iversen PL, Fletcher S, Wilton SD (2006), *Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD*. Gene Ther; 13: 1373-1381.
190. Yokota T, Lu QL, Partridge T, Kobayashi M, Nakamura A, Takeda S *et al.* (2009), *Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs*. Ann Neurol; 65: 667-676.
191. Fall AM, Johnsen R, Honeyman K, Iversen P, Fletcher S, Wilton SD (2006), *Induction of revertant fibres in the mdx mouse using antisense oligonucleotides*. Genet Vaccines Ther; 4: 3.
192. Aartsma-Rus A, Kaman WE, Weij R, den Dunnen JT, van Ommen GJ, van Deutekom JC (2006), *Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons*. Mol Ther; 14: 401-407.
193. van Vliet L, de Winter CL, van Deutekom JC, van Ommen GJ, Aartsma-Rus A (2008), *Assessment of the feasibility of exon 45-55 multiexon skipping for Duchenne muscular dystrophy*. BMC Med Genet; 9: 105.
194. Aoki Y, Yokota T, Nagata T, Nakamura A, Tanihata J, Saito T *et al.* (2012), *Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery*. Proc Natl Acad Sci USA; 109: 13763-13768.
195. Forrest S, Meloni PL, Muntoni F, Kim J, Fletcher S, Wilton SD (2010), *Personalized exon skipping strategies to address clustered non-deletion dystrophin mutations*. Neuromuscul Disord; 20: 810-816.
196. Mann CJ, Honeyman K, Cheng AJ, Ly T, Lloyd F, Fletcher S *et al.* (2001), *Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse*. Proc Natl Acad Sci USA; 98: 42-47.
197. Mann CJ, Honeyman K, McClorey G, Fletcher S, Wilton SD (2002), *Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy*. J Gene Med; 4: 644-654.

198. Lu QL, Mann CJ, Lou F, Bou-Gharios G, Morris GE, Xue SA *et al.* (2003), *Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse*. *Nat Med*; 9: 1009-1014.
199. Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J *et al.* (2005), *Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles*. *Proc Natl Acad Sci USA*; 102: 198-203.
200. Heemskerk H, de Winter C, van Kuik P, Heuvelmans N, Sabatelli P, Rimessi P *et al.* (2010), *Preclinical PK and PD studies on 2'-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model*. *Mol Ther*; 18: 1210-1217.
201. Tanganyika-de Winter CL, Heemskerk H, Karnaoukh TG, van Putten M, de Kimpe SJ, van Deutekom J *et al.* (2012), *Long-term exon skipping studies with 2'-O-methyl phosphorothioate antisense oligonucleotides in dystrophic mouse models*. *Mol Ther Nucleic Acids*; 1: e43.
202. Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, Wilton SD *et al.* (2006), *Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology*. *Nat Med*; 12: 175-177.
203. Wu B, Lu P, Benrashid E, Malik S, Ashar J, Doran TJ *et al.* (2010), *Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino*. *Gene Ther*; 17: 132-140.
204. Jearawiriyapaisarn N, Moulton HM, Buckley B, Roberts J, Sazani P, Fucharoen S *et al.* (2008), *Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice*. *Mol Ther*; 16: 1624-1629.
205. Wu B, Moulton HM, Iversen PL, Jiang J, Li J, Li J *et al.* (2008), *Effective rescue of dystrophin improves cardiac function in severely affected dystrophin-deficient mice by a modified morpholino oligomer*. *Proc Natl Acad Sci USA*; 105: 14814-14819.
206. Wu B, Lu P, Cloer C, Shaban M, Grewal S, Milazi S *et al.* (2012), *Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino*. *Am J Pathol*; 181: 392-400.
207. Goyenvallé A, Babbs A, Powell D, Kole R, Fletcher S, Wilton SD *et al.* (2010), *Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping*. *Mol Ther*; 18: 198-205.
208. Sazani P, Ness KP, Weller DL, Poage DW, Palyada K, Shrewsbury SB (2011), *Repeat-dose toxicology evaluation in cynomolgus monkeys of AVI-4658, a phosphorodiamidate morpholino oligomer (PMO) drug for the treatment of duchenne muscular dystrophy*. *Int J Toxicol*; 30: 313-321.
209. Yin H, Moulton HM, Betts C, Seow Y, Boutilier J, Iverson PL *et al.* (2009), *A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice*. *Hum Mol Genet*; 18: 4405-4414.
210. Ivanova GD, Arzumanov A, Abes R, Yin H, Wood MJ, Lebleu B *et al.* (2008), *Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle*. *Nucleic Acids Res*; 36: 6418-6428.
211. Yin H, Saleh AF, Betts C, Camelliti P, Seow Y, Ashraf S *et al.* (2011), *Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice*. *Mol Ther*; 19: 1295-1303.
212. Betts C, Saleh AF, Arzumanov AA, Hammond SM, Godfrey C, Coursindel T *et al.* (2012), *Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment*. *Mol Ther Nucleic Acids*; 1: e38.
213. Rimessi P, Sabatelli P, Fabris M, Braghetta P, Bassi E, Spitali P *et al.* (2009), *Cationic PMMA nanoparticles bind and deliver antisense oligoribonucleotides allowing restoration of dystrophin expression in the mdx mouse*. *Mol Ther*; 17: 820-827.
214. Ferlini A, Sabatelli P, Fabris M, Bassi E, Falzarano S, Vattemi G *et al.* (2010), *Dystrophin restoration in skeletal, heart and skin arrector pili smooth muscle of mdx mice by ZM2 NP-AON complexes*. *Gene Ther*; 17: 432-438.
215. Bassi E, Falzarano S, Fabris M, Gualandi F, Merlini L, Vattemi G *et al.* (2012), *Persistent dystrophin protein restoration 90 days after a course of intraperitoneally administered naked 2'OMePS AON and ZM2 NP-AON complexes in mdx mice*. *J Biomed Biotechnol*; 2012: 897076.
216. Mitrpant C, Fletcher S, Iversen PL, Wilton SD (2009), *By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping*. *J Gene Med*; 11: 46-56.
217. Bremmer-Bout M, Aartsma-Rus A, de Meijer EJ, Kaman WE, Janson AA, Vossen RH *et al.* (2004), *Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides*. *Mol Ther*; 10: 232-240.
218. Hoffman EP (2007), *Skipping toward personalized molecular medicine*. *N Engl J Med*; 357: 2719-2722.

219. Heemskerck H, de Winter CL, van Ommen GJ, van Deutekom JC, Aartsma-Rus A (2009), *Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy*. *Ann N Y Acad Sci*; 1175: 71-79.
220. Aoki Y, Nagata T, Yokota T, Nakamura A, Wood MJ, Partridge T *et al.* (2013), *Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-alpha2 chain-null congenital muscular dystrophy mice*. *Hum Mol Genet*; 22: 4914-4928.
221. Wu B, Benrashid E, Lu P, Cloer C, Zillmer A, Shaban M *et al.* (2011), *Targeted skipping of human dystrophin exons in transgenic mouse model systemically for antisense drug development*. *PLoS One*; 6: e19906.
222. Partridge T (2010), *The potential of exon skipping for treatment for Duchenne muscular dystrophy*. *J Child Neurol*; 25: 1165-1170.
223. Scheuerbrandt G (2009 Oct 3), *Research approaches for a therapy of Duchenne Muscular Dystrophy. Part I: Exon Skipping*. First update.
224. Yokota T, Nakamura A, Nagata T, Saito T, Kobayashi M, Aoki Y *et al.* (2012), *Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs*. *Nucleic Acid Ther*; 22: 306-315.
225. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M *et al.* (2007), *Local dystrophin restoration with antisense oligonucleotide PRO051*. *N Engl J Med*; 357: 2677-2686.
226. Kinali M, Arechavala-Gomez V, Feng L, Cirak S, Hunt D, Adkin C *et al.* (2009), *Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study*. *Lancet Neurol*; 8: 918-928.
227. Aartsma-Rus A, van Ommen GJ (2009), *Less is more: therapeutic exon skipping for Duchenne muscular dystrophy*. *Lancet Neurol*; 8: 873-875.
228. Takeshima Y, Yagi M, Wada H, Ishibashi K, Nishiyama A, Kakumoto M *et al.* (2006), *Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy*. *Pediatr Res*; 59: 690-694.
229. Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhardt PF, Heuvelmans N *et al.* (2011), *Systemic administration of PRO051 in Duchenne's muscular dystrophy*. *N Engl J Med*; 364: 1513-1522.
230. Flanigan KM, Voit T, Rosales XQ, Servais L, Kraus JE, Wardell C *et al.* (2013), *Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: Results of a double-blind randomized clinical trial*. *Neuromuscul Disord*.
231. Cirak S, Arechavala-Gomez V, Guglieri M, Feng L, Torelli S, Anthony K *et al.* (2011), *Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study*. *Lancet*; 378: 595-605.
232. http://www.gsk-clinicalstudyregister.com/result_compounds.jsp
233. <http://ir.prosensa.eu/releasedetail.cfm?ReleaseID=791929>
234. Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP *et al.* (2013), *Eteplirsen for the treatment of Duchenne muscular dystrophy*. *Ann Neurol*; 74: 637-647.
235. http://investorrelations.sareptatherapeutics.com/phoenix.zhtml?c=64231&p=irol-newsArticle_print&ID=1831214&highlight=
236. van den Bergen JC, Schade van Westrum SM, Dekker L, van der Kooij AJ, de VM, Wokke BH *et al.* (2014), *Clinical characterisation of Becker muscular dystrophy patients predicts favourable outcome in exon-skipping therapy*. *J Neurol Neurosurg Psychiatry*; 85: 92-98.
237. Henricson EK, Abresch RT, Cnaan A, Hu F, Duong T, Arrieta A *et al.* (2013), *The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures*. *Muscle Nerve*; 48: 55-67.
238. McDonald CM, Henricson EK, Abresch RT, Han JJ, Escolar DM, Florence JM *et al.* (2013), *The cooperative international neuromuscular research group Duchenne natural history study: a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used*. *Muscle Nerve*; 48: 32-54.
239. Malerba A, Thorogood FC, Dickson G, Graham IR (2009), *Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice*. *Hum Gene Ther*; 20: 955-965.
240. Verhaart IE, Tanganyika-de Winter CL, Karnaoukh TG, Kolfschoten IG, de Kimpe SJ, van Deutekom JC *et al.* (2013), *Dose-dependent pharmacokinetic profiles of 2'-O-methyl phosphorothioate antisense oligonucleotides in mdx mice*. *Nucleic Acid Ther*; 23: 228-237.
241. Moreno PM, Wenska M, Lundin KE, Wrangle O, Stromberg R, Smith CI (2009), *A synthetic snRNA m3G-CAP enhances nuclear delivery of exogenous proteins and nucleic acids*. *Nucleic Acids Res*; 37: 1925-1935.
242. De Angelis FG, Sthandier O, Berarducci B, Toso S, Galluzzi G, Ricci E *et al.* (2002), *Chimeric snRNA*

- molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells.* Proc Natl Acad Sci USA; 99: 9456-9461.
243. Denti MA, Rosa A, D'Antona G, Sthandier O, De Angelis FG, Nicoletti C *et al.* (2006), *Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model.* Proc Natl Acad Sci USA; 103: 3758-3763.
244. Denti MA, Incitti T, Sthandier O, Nicoletti C, De Angelis FG, Rizzuto E *et al.* (2008), *Long-term benefit of adeno-associated virus/antisense-mediated exon skipping in dystrophic mice.* Hum Gene Ther; 19: 601-608.
245. Goyenvalle A, Vulin A, Fougereousse F, Leturcq F, Kaplan JC, Garcia L *et al.* (2004), *Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping.* Science; 306: 1796-1799.
246. Brun C, Suter D, Pauli C, Dunant P, Lochmuller H, Burgunder JM *et al.* (2003), *U7 snRNAs induce correction of mutated dystrophin pre-mRNA by exon skipping.* Cell Mol Life Sci; 60: 557-566.
247. Incitti T, De Angelis FG, Cazzella V, Sthandier O, Pinnaro C, Legnini I *et al.* (2010), *Exon skipping and duchenne muscular dystrophy therapy: selection of the most active U1 snRNA antisense able to induce dystrophin exon 51 skipping.* Mol Ther; 18: 1675-1682.
248. Goyenvalle A, Babbs A, Wright J, Wilkins V, Powell D, Garcia L *et al.* (2012), *Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping.* Hum Mol Genet; 21: 2559-2571.
249. Eckenfelder A, Tordo J, Babbs A, Davies KE, Goyenvalle A, Danos O (2012), *The cellular processing capacity limits the amounts of chimeric U7 snRNA available for antisense delivery.* Mol Ther Nucleic Acids; 1: e31.
250. Goyenvalle A, Wright J, Babbs A, Wilkins V, Garcia L, Davies KE (2012), *Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy.* Mol Ther; 20: 1212-1221.
251. Vulin A, Barthelemy I, Goyenvalle A, Thibaud JL, Beley C, Griffith G *et al.* (2012), *Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping.* Mol Ther; 21: 2120-2133.
252. le Hir M, Goyenvalle A, Peccate C, Precigout G, Davies KE, Voit T *et al.* (2013), *AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy.* Mol Ther; 21: 1551-1558.
253. Shetty RS, Gallagher CS, Chen YT, Hims MM, Mull J, Leyne M *et al.* (2011), *Specific correction of a splice defect in brain by nutritional supplementation.* Hum Mol Genet; 20: 4093-4101.
254. Zhou J, Zheng X, Shen H (2012), *Targeting RNA-splicing for SMA treatment.* Mol Cells; 33: 223-228.
255. Nishida A, Kataoka N, Takeshima Y, Yagi M, Awano H, Ota M *et al.* (2011), *Chemical treatment enhances skipping of a mutated exon in the dystrophin gene.* Nat Commun; 2: 308.
256. Hu Y, Wu B, Zillmer A, Lu P, Benrashid E, Wang M *et al.* (2010), *Guanine analogues enhance antisense oligonucleotide-induced exon skipping in dystrophin gene in vitro and in vivo.* Mol Ther; 18: 812-818.
257. Verhaart IE, Aartsma-Rus A (2012), *The effect of 6-thioguanine on alternative splicing and antisense-mediated exon skipping treatment for duchenne muscular dystrophy.* PLoS Curr MD; 4.
258. Kendall GC, Mokhonova EI, Moran M, Sejbuk NE, Wang DW, Silva O *et al.* (2012), *Dantrolene enhances antisense-mediated exon skipping in human and mouse models of duchenne muscular dystrophy.* Sci Transl Med; 4: 164ra160.
259. Verhaart IE, Heemskerk H, Karnaoukh TG, Kolfshoten IG, Vroon A, van Ommen GJ *et al.* (2012), *Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy.* Hum Gene Ther; 23: 262-273.
260. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT *et al.* (2007), *Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states.* Nat Med; 13: 204-210.
261. Bish LT, Yarchoan M, Sleeper MM, Gazzara JA, Morine KJ, Acosta P *et al.* (2011), *Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice.* PLoS One; 6: e20856.
262. Habashi JP, Doyle JJ, Holm TM, Aziz H, Schoenhoff F, Bedja D *et al.* (2011), *Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism.* Science; 332: 361-365.
263. Nelson CA, Hunter RB, Quigley LA, Girgenrath S, Weber WD, McCullough JA *et al.* (2011), *Inhibiting TGF-beta activity improves respiratory function in mdx mice.* Am J Pathol; 178: 2611-2621.
264. Spurney CF, Sali A, Gueron AD, Iantorno M, Yu Q, Gordish-Dressman H *et al.* (2011), *Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice.* J Cardiovasc Pharmacol Ther; 16: 87-95.
265. Howard MT, Anderson CB, Fass U, Khatri S, Gesteland RF, Atkins JF *et al.* (2004), *Readthrough of dystrophin stop codon mutations induced by aminoglycosides.* Ann Neurol; 55: 422-426.

266. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL (1999), *Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice*. J Clin Invest; 104: 375-381.
267. Dunant P, Walter MC, Karpati G, Lochmuller H (2003), *Gentamicin fails to increase dystrophin expression in dystrophin-deficient muscle*. Muscle Nerve; 27: 624-627.
268. Politano L, Nigro G, Nigro V, Piluso G, Papparella S, Paciello O *et al.* (2003), *Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results*. Acta Myol; 22: 15-21.
269. Aartsma-Rus A, den Dunnen JT, van Ommen GJ (2010), *New insights in gene-derived therapy: the example of Duchenne muscular dystrophy*. Ann N Y Acad Sci; 1214: 199-212.
270. Malik V, Rodino-Klapac LR, Viollet L, Mendell JR (2010), *Aminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophy*. Ther Adv Neurol Disord; 3: 379-389.
271. Bönnemann C, Finkel R, Wong B, Flanigan K, Sampson J, Sweeney L *et al.* (2007) *G.P.3.05 Phase 2 study of PTC124 for nonsense mutation suppression therapy of Duchenne muscular dystrophy (DMD)*. Neuro-muscul Disord 17[9], 783.
272. Hirawat S, Welch EM, Elfring GL, Northcutt VJ, Paushkin S, Hwang S *et al.* (2007), *Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers*. J Clin Pharmacol; 47: 430-444.
273. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P *et al.* (2007), *PTC124 targets genetic disorders caused by nonsense mutations*. Nature; 447: 87-91.
274. Finkel RS (2010), *Read-through strategies for suppression of nonsense mutations in Duchenne/Becker muscular dystrophy: aminoglycosides and ataluren (PTC124)*. J Child Neurol; 25: 1158-1164.
275. Hoffman EP, Bronson A, Levin AA, Takeda S, Yokota T, Baudy AR *et al.* (2011), *Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through*. Am J Pathol; 179: 12-22.
276. Auld DS, Thorne N, Maguire WF, Inglese J (2009), *Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression*. Proc Natl Acad Sci USA; 106: 3585-3590.
277. Auld DS, Lovell S, Thorne N, Lea WA, Maloney DJ, Shen M *et al.* (2010), *Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124*. Proc Natl Acad Sci USA; 107: 4878-4883.
278. Du M, Liu X, Welch EM, Hirawat S, Peltz SW, Bedwell DM (2008), *PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model*. Proc Natl Acad Sci USA; 105: 2064-2069.
279. Kayali R, Ku JM, Khitrov G, Jung ME, Prikhodko O, Bertoni C (2012), *Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy*. Hum Mol Genet; 21: 4007-4020.
280. Linde L, Boelz S, Nissim-Rafinia M, Oren YS, Wilschanski M, Yaacov Y *et al.* (2007), *Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin*. J Clin Invest; 117: 683-692.
281. Puttaraju M, Jamison SF, Mansfield SG, Garcia-Blanco MA, Mitchell LG (1999), *Spliceosome-mediated RNA trans-splicing as a tool for gene therapy*. Nat Biotechnol; 17: 246-252.
282. Chao H, Mansfield SG, Bartel RC, Hiriyanna S, Mitchell LG, Garcia-Blanco MA *et al.* (2003), *Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing*. Nat Med; 9: 1015-1019.
283. Mansfield SG, Clark RH, Puttaraju M, Kole J, Cohn JA, Mitchell LG *et al.* (2003), *5' exon replacement and repair by spliceosome-mediated RNA trans-splicing*. RNA; 9: 1290-1297.
284. Lorain S, Peccate C, le HM, Garcia L (2010), *Exon exchange approach to repair Duchenne dystrophin transcripts*. PLoS One; 5: e10894.
285. Lorain S, Peccate C, le HM, Griffith G, Philippi S, Precigout G *et al.* (2013), *Dystrophin rescue by trans-splicing: a strategy for DMD genotypes not eligible for exon skipping approaches*. Nucleic Acids Res; 41: 8391-8402.
286. Romero NB, Braun S, Benveniste O, Leturcq F, Hogrel JY, Morris GE *et al.* (2004), *Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy*. Hum Gene Ther; 15: 1065-1076.
287. van Deutekom JC, van Ommen GJ (2003), *Advances in Duchenne muscular dystrophy gene therapy*. Nat Rev Genet; 4: 774-783.
288. Harper SQ, Hauser MA, DelloRusso C, Duan D, Crawford RW, Phelps SF *et al.* (2002), *Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy*. Nat Med; 8: 253-261.
289. Blankinship MJ, Gregorevic P, Chamberlain JS (2006), *Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors*. Mol Ther; 13: 241-249.
290. England SB, Nicholson LV, Johnson MA, Forrest SM, Love DR, Zubrzycka-Gaarn EE *et al.* (1990), *Very*

- mild muscular dystrophy associated with the deletion of 46% of dystrophin*. Nature; 343: 180-182.
291. Wang B, Li J, Xiao X (2000), *Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model*. Proc Natl Acad Sci USA; 97: 13714-13719.
292. Wang B, Li J, Qiao C, Chen C, Hu P, Zhu X *et al.* (2008), *A canine minidystrophin is functional and therapeutic in mdx mice*. Gene Ther; 15: 1099-1106.
293. Fabb SA, Wells DJ, Serpente P, Dickson G (2002), *Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micro-dystrophin effectively restores the dystrophin-associated protein complex and inhibits myofibre degeneration in nude/mdx mice*. Hum Mol Genet; 11: 733-741.
294. Liu M, Yue Y, Harper SQ, Grange RW, Chamberlain JS, Duan D (2005), *Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury*. Mol Ther; 11: 245-256.
295. Townsend D, Yasuda S, Li S, Chamberlain JS, Metzger JM (2008), *Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle*. Mol Ther; 16: 832-835.
296. Crisp A, Yin H, Goyenville A, Betts C, Moulton HM, Seow Y *et al.* (2011), *Diaphragm rescue alone prevents heart dysfunction in dystrophic mice*. Hum Mol Genet; 20: 413-421.
297. Wasala NB, Bostick B, Yue Y, Duan D (2013), *Exclusive skeletal muscle correction does not modulate dystrophic heart disease in the aged mdx model of Duchenne cardiomyopathy*. Hum Mol Genet; 22: 2634-2641.
298. Gregorevic P, Blankinship MJ, Allen JM, Crawford RW, Meuse L, Miller DG *et al.* (2004), *Systemic delivery of genes to striated muscles using adeno-associated viral vectors*. Nat Med; 10: 828-834.
299. Gregorevic P, Blankinship MJ, Allen JM, Chamberlain JS (2008), *Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice*. Mol Ther; 16: 657-664.
300. Wang Z, Tapscott SJ, Chamberlain JS, Storb R (2011), *Immunity and AAV-mediated gene therapy for muscular dystrophies in large animal models and human trials*. Front Microbiol; 2: 201.
301. Wang Z, Allen JM, Riddell SR, Gregorevic P, Storb R, Tapscott SJ *et al.* (2007), *Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy*. Hum Gene Ther; 18: 18-26.
302. Wang Z, Storb R, Lee D, Kushmerick MJ, Chu B, Berger C *et al.* (2010), *Immune responses to AAV in canine muscle monitored by cellular assays and noninvasive imaging*. Mol Ther; 18: 617-624.
303. Yue Y, Ghosh A, Long C, Bostick B, Smith BF, Kornegay JN *et al.* (2008), *A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs*. Mol Ther; 16: 1944-1952.
304. Ohshima S, Shin JH, Yuasa K, Nishiyama A, Kira J, Okada T *et al.* (2009), *Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle*. Mol Ther; 17: 73-80.
305. Gregorevic P, Schultz BR, Allen JM, Halldorson JB, Blankinship MJ, Mezmarich NA *et al.* (2009), *Evaluation of vascular delivery methodologies to enhance rAAV6-mediated gene transfer to canine striated musculature*. Mol Ther; 17: 1427-1433.
306. Kornegay JN, Li J, Bogan JR, Bogan DJ, Chen C, Zheng H *et al.* (2010), *Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs*. Mol Ther; 18: 1501-1508.
307. Toromanoff A, Adjali O, Larcher T, Hill M, Guigand L, Chenuaud P *et al.* (2010), *Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle*. Mol Ther; 18: 151-160.
308. Rodino-Klapac LR, Montgomery CL, Bremer WG, Shontz KM, Malik V, Davis N *et al.* (2010), *Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery*. Mol Ther; 18: 109-117.
309. Bowles DE, McPhee SW, Li C, Gray SJ, Samulski JJ, Camp AS *et al.* (2012), *Phase I gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector*. Mol Ther; 20: 443-455.
310. Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S *et al.* (2010), *Dystrophin immunity in Duchenne's muscular dystrophy*. N Engl J Med; 363: 1429-1437.
311. Ghosh A, Yue Y, Shin JH, Duan D (2009), *Systemic Trans-splicing adeno-associated viral delivery efficiently transduces the heart of adult mdx mouse, a model for duchenne muscular dystrophy*. Hum Gene Ther; 20: 1319-1328.
312. Odom GL, Gregorevic P, Allen JM, Chamberlain JS (2011), *Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6*. Mol Ther; 19: 36-45.
313. Zhang Y, Duan D (2012), *Novel mini-dystrophin gene dual adeno-associated virus vectors restore neuronal nitric oxide synthase expression at the sarcolemma*. Hum Gene Ther; 23: 98-103.
314. Ishizaki M, Maeda Y, Kawano R, Suga T, Uchida Y, Uchino K *et al.* (2011), *Rescue from respiratory*

- dysfunction by transduction of full-length dystrophin to diaphragm via the peritoneal cavity in utrophin/dystrophin double knockout mice. *Mol Ther*; 19: 1230-1235.
315. Koo T, Okada T, Athanasopoulos T, Foster H, Takeda S, Dickson G (2011), *Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog*. *J Gene Med*; 13: 497-506.
316. Shin JH, Yue Y, Srivastava A, Smith B, Lai Y, Duan D (2012), *A simplified immune suppression scheme leads to persistent micro-dystrophin expression in duchenne muscular dystrophy dogs*. *Hum Gene Ther*; 23: 202-209.
317. Shin JH, Pan X, Hakim CH, Yang HT, Yue Y, Zhang K *et al.* (2013), *Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy*. *Mol Ther*; 21: 750-757.
318. Evans VC, Graham IR, Athanasopoulos T, Galley DJ, Jackson CL, Simons JP *et al.* (2011), *Adeno-associated virus serotypes 7 and 8 outperform serotype 9 in expressing atheroprotective human apoE3 from mouse skeletal muscle*. *Metabolism*; 60: 491-498.
319. Gao G, Bish LT, Sleeper MM, Mu X, Sun L, Lou Y *et al.* (2011), *Transendocardial delivery of AAV6 results in highly efficient and global cardiac gene transfer in rhesus macaques*. *Hum Gene Ther*; 22: 979-984.
320. Zincarelli C, Soltys S, Rengo G, Koch WJ, Rabinowitz JE (2010), *Comparative cardiac gene delivery of adeno-associated virus serotypes 1-9 reveals that AAV6 mediates the most efficient transduction in mouse heart*. *Clin Transl Sci*; 3: 81-89.
321. Moulay G, Boutin S, Masurier C, Scherman D, Kichler A (2010), *Polymers for improving the in vivo transduction efficiency of AAV2 vectors*. *PLoS One*; 5: e15576.
322. Hegge JO, Wooddell CI, Zhang G, Hagstrom JE, Braun S, Huss T *et al.* (2010), *Evaluation of hydrodynamic limb vein injections in nonhuman primates*. *Hum Gene Ther*; 21: 829-842.
323. Qiao C, Li J, Zheng H, Bogan J, Li J, Yuan Z *et al.* (2009), *Hydrodynamic limb vein injection of adeno-associated virus serotype 8 vector carrying canine myostatin propeptide gene into normal dogs enhances muscle growth*. *Hum Gene Ther*; 20: 1-10.
324. Wooddell CI, Hegge JO, Zhang G, Sebestyen MG, Noble M, Griffin JB *et al.* (2011), *Dose response in rodents and nonhuman primates after hydrodynamic limb vein delivery of naked plasmid DNA*. *Hum Gene Ther*; 22: 889-903.
325. Zhang G, Wooddell CI, Hegge JO, Griffin JB, Huss T, Braun S *et al.* (2010), *Functional efficacy of dystrophin expression from plasmids delivered to mdx mice by hydrodynamic limb vein injection*. *Hum Gene Ther*; 21: 221-237.
326. Fan Z, Kocis K, Valley R, Howard JF, Chopra M, An H *et al.* (2012), *Safety and feasibility of high-pressure transvenous limb perfusion with 0.9% saline in human muscular dystrophy*. *Mol Ther*; 20: 456-461.
327. Bish LT, Sleeper MM, Forbes SC, Wang B, Reynolds C, Singletary GE *et al.* (2012), *Long-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping*. *Mol Ther*; 20: 580-589.
328. Bostick B, Shin JH, Yue Y, Duan D (2011), *AAV-microdystrophin therapy improves cardiac performance in aged female mdx mice*. *Mol Ther*; 19: 1826-1832.
329. Schinkel S, Bauer R, Bekeredjian R, Stucka R, Rutschow D, Lochmuller H *et al.* (2012), *Long-term preservation of cardiac structure and function after adeno-associated virus serotype 9-mediated microdystrophin gene transfer in mdx mice*. *Hum Gene Ther*; 23: 566-575.
330. Shin JH, Nitahara-Kasahara Y, Hayashita-Kinoh H, Ohshima-Hosoyama S, Kinoshita K, Chiyo T *et al.* (2011), *Improvement of cardiac fibrosis in dystrophic mice by rAAV9-mediated microdystrophin transduction*. *Gene Ther*; 18: 910-919.
331. Peault B, Rudnicki M, Torrente Y, Cossu G, Tremblay JP, Partridge T *et al.* (2007), *Stem and progenitor cells in skeletal muscle development, maintenance, and therapy*. *Mol Ther*; 15: 867-877.
332. Skuk D, Roy B, Goulet M, Chapdelaine P, Bouchard JP, Roy R *et al.* (2004), *Dystrophin expression in myofibers of Duchenne muscular dystrophy patients following intramuscular injections of normal myogenic cells*. *Mol Ther*; 9: 475-482.
333. Skuk D, Tremblay JP (2011), *Intramuscular cell transplantation as a potential treatment of myopathies: clinical and preclinical relevant data*. *Expert Opin Biol Ther*; 11: 359-374.
334. Montarras D, Morgan J, Collins C, Relaix F, Zaffran S, Cumano A *et al.* (2005), *Direct isolation of satellite cells for skeletal muscle regeneration*. *Science*; 309: 2064-2067.
335. Urish K, Kanda Y, Huard J (2005), *Initial failure in myoblast transplantation therapy has led the way toward the isolation of muscle stem cells: potential for tissue regeneration*. *Curr Top Dev Biol*; 68: 263-280.
336. Tsao J, Vernet DA, Gelfand R, Kovanez I, Nolzco G, Bruhn KW *et al.* (2013), *Myostatin genetic inactivation inhibits myogenesis by muscle derived stem cells in vitro but not when implanted in the mdx mouse muscle*. *Stem Cell Res Ther*; 4: 4.
337. Sampaolesi M, Blot S, D'Antona G, Granger N, Tonlorenzi R, Innocenzi A *et al.* (2006), *Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs*. *Nature*; 444: 574-579.

338. Morgan J, Muntoni F (2007), *Mural cells paint a new picture of muscle stem cells*. *Nat Cell Biol*; 9: 249-251.
339. Vieira NM, Valadares M, Zucconi E, Secco M, Bueno Junior CR, Brandalise V *et al.* (2012), *Human adipose-derived mesenchymal stromal cells injected systemically into GRMD dogs without immunosuppression are able to reach the host muscle and express human dystrophin*. *Cell Transplant*; 21: 1407-1417.
340. Fakhfakh R, Michaud A, Tremblay JP (2011), *Blocking the myostatin signal with a dominant negative receptor improves the success of human myoblast transplantation in dystrophic mice*. *Mol Ther*; 19: 204-210.
341. Foster H, Popplewell L, Dickson G (2012), *Genetic therapeutic approaches for Duchenne muscular dystrophy*. *Hum Gene Ther*; 23: 676-687.
342. Chapdelaine P, Pichavant C, Rousseau J, Paques F, Tremblay JP (2010), *Meganucleases can restore the reading frame of a mutated dystrophin*. *Gene Ther*; 17: 846-858.
343. Rousseau J, Chapdelaine P, Boisvert S, Almeida LP, Corbeil J, Montpetit A *et al.* (2011), *Endonucleases: tools to correct the dystrophin gene*. *J Gene Med*; 13: 522-537.
344. Popplewell L, Koo T, Leclerc X, Duclert A, Mamchaoui K, Gouble A *et al.* (2013), *Gene correction of a duchenne muscular dystrophy mutation by meganuclease-enhanced exon knock-in*. *Hum Gene Ther*; 24: 692-701.
345. Ousterout DG, Perez-Pinera P, Thakore PI, Kabadi AM, Brown MT, Qin X *et al.* (2013), *Reading frame correction by targeted genome editing restores dystrophin expression in cells from duchenne muscular dystrophy patients*. *Mol Ther*; 21: 1718-1726.
346. Deconinck N, Tinsley J, De BF, Fisher R, Kahn D, Phelps S *et al.* (1997), *Expression of truncated utrophin leads to major functional improvements in dystrophin-deficient muscles of mice*. *Nat Med*; 3: 1216-1221.
347. Gillis JM (2002), *Multivariate evaluation of the functional recovery obtained by the overexpression of utrophin in skeletal muscles of the mdx mouse*. *Neuromuscul Disord*; 12 Suppl 1: S90-S94.
348. Tinsley J, Deconinck N, Fisher R, Kahn D, Phelps S, Gillis JM *et al.* (1998), *Expression of full-length utrophin prevents muscular dystrophy in mdx mice*. *Nat Med*; 4: 1441-1444.
349. Cerletti M, Negri T, Cozzi F, Colpo R, Andretta F, Croci D *et al.* (2003), *Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer*. *Gene Ther*; 10: 750-757.
350. Moorwood C, Khurana TS (2013), *Duchenne muscular dystrophy drug discovery - the application of utrophin promoter activation screening*. *Expert Opin Drug Discov*; 8: 569-581.
351. Tinsley JM, Fairclough RJ, Storer R, Wilkes FJ, Potter AC, Squire SE *et al.* (2011), *Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse*. *PLoS One*; 6: e19189.
352. <http://www.summitplc.com/programmes/publications/>
353. Li D, Bareja A, Judge L, Yue Y, Lai Y, Fairclough R *et al.* (2010), *Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin*. *J Cell Sci*; 123: 2008-2013.
354. Bowe MA, Mendis DB, Fallon JR (2000), *The small leucine-rich repeat proteoglycan biglycan binds to alpha-dystroglycan and is upregulated in dystrophic muscle*. *J Cell Biol*; 148: 801-810.
355. Amenta AR, Yilmaz A, Bogdanovich S, McKechnie BA, Abedi M, Khurana TS *et al.* (2011), *Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice*. *Proc Natl Acad Sci USA*; 108: 762-767.
356. Amirouche A, Tadesse H, Lunde JA, Belanger G, Cote J, Jasmin BJ (2013), *Activation of p38 signaling increases utrophin A expression in skeletal muscle via the RNA-binding protein KSRP and inhibition of AU-rich element-mediated mRNA decay: implications for novel DMD therapeutics*. *Hum Mol Genet*; 22: 3093-3111.
357. Kharraz Y, Guerra J, Mann CJ, Serrano AL, Munoz-Canoves P (2013), *Macrophage plasticity and the role of inflammation in skeletal muscle repair*. *Mediators Inflamm*; 2013: 491497.
358. Spencer MJ, Tidball JG (2001), *Do immune cells promote the pathology of dystrophin-deficient myopathies?* *Neuromuscul Disord*; 11: 556-564.
359. Spencer MJ, Montecino-Rodriguez E, Dorshkind K, Tidball JG (2001), *Helper (CD4(+)) and cytotoxic (CD8(+)) T cells promote the pathology of dystrophin-deficient muscle*. *Clin Immunol*; 98: 235-243.
360. Wynn TA (2004), *Fibrotic disease and the T(H)1/T(H)2 paradigm*. *Nat Rev Immunol*; 4: 583-594.
361. Zhou L, Lu H (2010), *Targeting fibrosis in Duchenne muscular dystrophy*. *J Neuropathol Exp Neurol*; 69: 771-776.
362. Wehling M, Spencer MJ, Tidball JG (2001), *A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice*. *J Cell Biol*; 155: 123-131.
363. Villalta SA, Nguyen HX, Deng B, Gotoh T, Tidball JG (2009), *Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy*.

- Hum Mol Genet; 18: 482-496.
364. Wehling-Henricks M, Sokolow S, Lee JJ, Myung KH, Villalta SA, Tidball JG (2008), *Major basic protein-1 promotes fibrosis of dystrophic muscle and attenuates the cellular immune response in muscular dystrophy*. Hum Mol Genet; 17: 2280-2292.
365. Yoshizawa I, Nakajima T, Kawano Y, Noma T (1994), *Suppressive effect of oxatomide on the induction of IL2 responsiveness by DF-stimulated lymphocytes from patients with bronchial asthma*. Arerugi; 43: 535-543.
366. Gorospe JR, Tharp MD, Hinckley J, Kornegay JN, Hoffman EP (1994), *A role for mast cells in the progression of Duchenne muscular dystrophy? Correlations in dystrophin-deficient humans, dogs, and mice*. J Neurol Sci; 122: 44-56.
367. Gorospe JR, Tharp M, Demitsu T, Hoffman EP (1994), *Dystrophin-deficient myofibers are vulnerable to mast cell granule-induced necrosis*. Neuromuscul Disord; 4: 325-333.
368. Khan MA (1993), *Corticosteroid therapy in Duchenne muscular dystrophy*. J Neurol Sci; 120: 8-14.
369. Gaud A, Simon JM, Witzel T, Carre-Pierrat M, Wermuth CG, Segalat L (2004), *Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans*. Neuromuscul Disord; 14: 365-370.
370. Wuebbles RD, Sarathy A, Kornegay JN, Burkin DJ (2013), *Levels of alpha7 integrin and laminin-alpha2 are increased following prednisone treatment in the mdx mouse and GRMD dog models of Duchenne muscular dystrophy*. Dis Model Mech; 6: 1175-1184.
371. Baltgalvis KA, Call JA, Nikas JB, Lowe DA (2009), *Effects of prednisolone on skeletal muscle contractility in mdx mice*. Muscle Nerve; 40: 443-454.
372. Tamma R, Annese T, Capogrosso RF, Cozzoli A, Benaglio V, Sblendorio V et al. (2013), *Effects of prednisolone on the dystrophin-associated proteins in the blood-brain barrier and skeletal muscle of dystrophic mdx mice*. Lab Invest; 93: 592-610.
373. Kolodziejczyk SM, Walsh GS, Balazsi K, Seale P, Sandoz J, Hierlihy AM et al. (2001), *Activation of JNK1 contributes to dystrophic muscle pathogenesis*. Curr Biol; 11: 1278-1282.
374. St-Pierre SJ, Chakkalakal JV, Kolodziejczyk SM, Knudson JC, Jasmin BJ, Megency LA (2004), *Glucocorticoid treatment alleviates dystrophic myofiber pathology by activation of the calcineurin/NF-AT pathway*. FASEB J; 18: 1937-1939.
375. Fisher I, Abraham D, Bouri K, Hoffman EP, Muntoni F, Morgan J (2005), *Prednisolone-induced changes in dystrophic skeletal muscle*. FASEB J; 19: 834-836.
376. Jobling AI, Augusteyn RC (2002), *What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts*. Clin Exp Optom; 85: 61-75.
377. Lo Cascio V, Kanis JA, Beneton MN, Bertoldo F, Adami S, Poggi G et al. (1995), *Acute effects of deflazacort and prednisone on rates of mineralization and bone formation*. Calcif Tissue Int; 56: 109-112.
378. Schakman O, Gilson H, Kalista S, Thissen JP (2009), *Mechanisms of muscle atrophy induced by glucocorticoids*. Horm Res; 72 Suppl 1: 36-41.
379. Guerron AD, Rawat R, Sali A, Spurney CF, Pistilli E, Cha HJ et al. (2010), *Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne muscular dystrophy*. PLoS One; 5: e11220.
380. Sali A, Guerron AD, Gordish-Dressman H, Spurney CF, Iantorno M, Hoffman EP et al. (2012), *Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouse*. PLoS One; 7: e34204.
381. Bauer R, Straub V, Blain A, Bushby K, MacGowan GA (2009), *Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy*. Eur J Heart Fail; 11: 463-471.
382. Markham LW, Kinnett K, Wong BL, Woodrow BD, Cripe LH (2008), *Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy*. Neuromuscul Disord; 18: 365-370.
383. Silversides CK, Webb GD, Harris VA, Biggar DW (2003), *Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy*. Am J Cardiol; 91: 769-772.
384. Bonifati MD, Ruzza G, Bonometto P, Berardinelli A, Gorni K, Orcesi S et al. (2000), *A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy*. Muscle Nerve; 23: 1344-1347.
385. Merlini L, Gennari M, Malaspina E, Cecconi I, Armaroli A, Gnudi S et al. (2012), *Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up*. Muscle Nerve; 45: 796-802.
386. Backman E, Henriksson KG (1995), *Low-dose prednisolone treatment in Duchenne and Becker muscular dystrophy*. Neuromuscul Disord; 5: 233-241.
387. Connolly AM, Schierbecker J, Renna R, Florence J (2002), *High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy*. Neuromuscul Disord; 12: 917-925.

388. Escolar DM, Hache LP, Clemens PR, Cnaan A, McDonald CM, Viswanathan V *et al.* (2011), *Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy*. *Neurology*; 77: 444-452.
389. Fenichel GM, Mendell JR, Moxley RT, III, Griggs RC, Brooke MH, Miller JP *et al.* (1991), *A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy*. *Arch Neurol*; 48: 575-579.
390. Kinali M, Mercuri E, Main M, Muntoni F, Dubowitz V (2002), *An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy*. *Neuromuscul Disord*; 12 Suppl 1: S169-S174.
391. Serra F, Quarta M, Canato M, Toniolo L, De A, V, Trotta A *et al.* (2012), *Inflammation in muscular dystrophy and the beneficial effects of non-steroidal anti-inflammatory drugs*. *Muscle Nerve*; 46: 773-784.
392. Pierno S, Nico B, Burdi R, Liantonio A, Didonna MP, Cippone V *et al.* (2007), *Role of tumour necrosis factor alpha, but not of cyclo-oxygenase-2-derived eicosanoids, on functional and morphological indices of dystrophic progression in mdx mice: a pharmacological approach*. *Neuropathol Appl Neurobiol*; 33: 344-359.
393. Brunelli S, Sciorati C, D'Antona G, Innocenzi A, Covarello D, Galvez BG *et al.* (2007), *Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy*. *Proc Natl Acad Sci USA*; 104: 264-269.
394. Thomas GD, Ye J, De NC, Monopoli A, Ongini E, Victor RG (2012), *Treatment with a nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse model of Duchenne muscular dystrophy*. *PLoS One*; 7: e49350.
395. Pereira JA, Taniguti AP, Matsumura C, Marques MJ, Neto HS (2012), *Doxycycline ameliorates the dystrophic phenotype of skeletal and cardiac muscles in mdx mice*. *Muscle Nerve*; 46: 400-406.
396. Hori YS, Kuno A, Hosoda R, Tanno M, Miura T, Shimamoto K *et al.* (2011), *Resveratrol ameliorates muscular pathology in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy*. *J Pharmacol Exp Ther*; 338: 784-794.
397. Kuno A, Hori YS, Hosoda R, Tanno M, Miura T, Shimamoto K *et al.* (2013), *Resveratrol improves cardiomyopathy in dystrophin-deficient mice through SIRT1 protein-mediated modulation of p300 protein*. *J Biol Chem*; 288: 5963-5972.
398. Gordon BS, Delgado Diaz DC, Kostek MC (2013), *Resveratrol decreases inflammation and increases utrophin gene expression in the mdx mouse model of Duchenne muscular dystrophy*. *Clin Nutr*; 32: 104-111.
399. Selsby JT, Morine KJ, Pendrak K, Barton ER, Sweeney HL (2012), *Rescue of dystrophic skeletal muscle by PGC-1alpha involves a fast to slow fiber type shift in the mdx mouse*. *PLoS One*; 7: e30063.
400. Patella V, de CG, Marino O, Spadaro G, Genovese A, Marone G (1996), *Oxatomide inhibits the release of proinflammatory mediators from human basophils and mast cells*. *Int Arch Allergy Immunol*; 111: 23-29.
401. Granchelli JA, Pollina C, Hudecki MS (2000), *Pre-clinical screening of drugs using the mdx mouse*. *Neuromuscul Disord*; 10: 235-239.
402. Buyse GM, Goemans N, Henricson E, Jara A, van den Hauwe M, Leshner R *et al.* (2007), *CINRG pilot trial of oxatomide in steroid-naive Duchenne muscular dystrophy*. *Eur J Paediatr Neurol*; 11: 337-340.
403. Lau KS, Grange RW, Chang WJ, Kamm KE, Sarelius I, Stull JT (1998), *Skeletal muscle contractions stimulate cGMP formation and attenuate vascular smooth muscle myosin phosphorylation via nitric oxide*. *FEBS Lett*; 431: 71-74.
404. Ennen JP, Verma M, Asakura A (2013), *Vascular-targeted therapies for Duchenne muscular dystrophy*. *Skelet Muscle*; 3: 9.
405. Cvelich RG, Roberts SC, Brown JN (2011), *Phosphodiesterase type 5 inhibitors as adjunctive therapy in the management of systolic heart failure*. *Ann Pharmacother*; 45: 1551-1558.
406. Dorsey P, Keel C, Klavens M, Hellstrom WJ (2010), *Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction*. *Expert Opin Pharmacother*; 11: 1109-1122.
407. Kawahara G, Karpf JA, Myers JA, Alexander MS, Guyon JR, Kunkel LM (2011), *Drug screening in a zebrafish model of Duchenne muscular dystrophy*. *Proc Natl Acad Sci USA*; 108: 5331-5336.
408. Adamo CM, Dai DF, Percival JM, Minami E, Willis MS, Patrucco E *et al.* (2010), *Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy*. *Proc Natl Acad Sci USA*; 107: 19079-19083.
409. Percival JM, Whitehead NP, Adams ME, Adamo CM, Beavo JA, Froehner SC (2012), *Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy*. *J Pathol*; 228: 77-87.
410. Percival JM, Siegel MP, Knowels G, Marcinek DJ (2013), *Defects in mitochondrial localization and ATP synthesis in the mdx mouse model of Duchenne muscular dystrophy are not alleviated by PDE5 inhibition*. *Hum Mol Genet*; 22: 153-167.
411. Koitabashi N, Aiba T, Hesketh GG, Rowell J, Zhang M, Takimoto E *et al.* (2010), *Cyclic GMP/PKG-de-*

- pendent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation. *Novel mechanism of cardiac stress modulation by PDE5 inhibition*. *J Mol Cell Cardiol*; 48: 713-724.
412. Zhao S, Zhang L, Lian G, Wang X, Zhang H, Yao X *et al.* (2011), *Sildenafil attenuates LPS-induced pro-inflammatory responses through down-regulation of intracellular ROS-related MAPK/NF-kappaB signaling pathways in N9 microglia*. *Int Immunopharmacol*; 11: 468-474.
 413. Asai A, Sahani N, Kaneki M, Ouchi Y, Martyn JA, Yasuhara SE (2007), *Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy*. *PLoS One*; 2: e806.
 414. Martin EA, Barresi R, Byrne BJ, Tsimerinov EI, Scott BL, Walker AE *et al.* (2012), *Tadalafil alleviates muscle ischemia in patients with becker muscular dystrophy*. *Sci Transl Med*; 4: 162ra155.
 415. Mizunoya W, Upadhyaya R, Burczynski FJ, Wang G, Anderson JE (2011), *Nitric oxide donors improve prednisone effects on muscular dystrophy in the mdx mouse diaphragm*. *Am J Physiol Cell Physiol*; 300: C1065-C1077.
 416. Kim JH, Kwak HB, Thompson LV, Lawler JM (2013), *Contribution of oxidative stress to pathology in diaphragm and limb muscles with Duchenne muscular dystrophy*. *J Muscle Res Cell Motil*; 34: 1-13.
 417. McGeachie JK, Grounds MD, Partridge TA, Morgan JE (1993), *Age-related changes in replication of myogenic cells in mdx mice: quantitative autoradiographic studies*. *J Neurol Sci*; 119: 169-179.
 418. Pastoret C, Sebillé A (1995), *Age-related differences in regeneration of dystrophic (mdx) and normal muscle in the mouse*. *Muscle Nerve*; 18: 1147-1154.
 419. Stedman HH, Sweeney HL, Shrager JB, Maguire HC, Panettieri RA, Petrof B *et al.* (1991), *The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy*. *Nature*; 352: 536-539.
 420. Spurney CF, Rocha CT, Henricson E, Florence J, Mayhew J, Gorni K *et al.* (2011), *CINRG pilot trial of coenzyme Q10 in steroid-treated Duchenne muscular dystrophy*. *Muscle Nerve*; 44: 174-178.
 421. Nagy I (1990), *Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review*. *Arch Gerontol Geriatr*; 11: 177-186.
 422. Buyse GM, Van der MG, Erb M, D'hooge J, Herijgers P, Verbeken E *et al.* (2009), *Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance*. *Eur Heart J*; 30: 116-124.
 423. Buyse GM, Goemans N, van den Hauwe M, Thijs D, de Groot IJ, Schara U *et al.* (2011), *Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial*. *Neuromuscul Disord*; 21: 396-405.
 424. Buyse GM, Goemans N, van den Hauwe M, Meier T (2013), *Effects of glucocorticoids and idebenone on respiratory function in patients with duchenne muscular dystrophy*. *Pediatr Pulmonol*; 48: 912-920.
 425. Evans NP, Misyak SA, Robertson JL, Bassaganya-Riera J, Grange RW (2009), *Immune-mediated mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy and provide targets for therapeutic intervention*. *PM R*; 1: 755-768.
 426. Porter JD, Khanna S, Kaminski HJ, Rao JS, Merriam AP, Richmonds CR *et al.* (2002), *A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice*. *Hum Mol Genet*; 11: 263-272.
 427. Tidball JG (2005), *Inflammatory processes in muscle injury and repair*. *Am J Physiol Regul Integr Comp Physiol*; 288: R345-R353.
 428. Acharyya S, Villalta SA, Bakkar N, Bupha-Intr T, Janssen PM, Carathers M *et al.* (2007), *Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy*. *J Clin Invest*; 117: 889-901.
 429. Hayden MS, Ghosh S (2004), *Signaling to NF-kappaB*. *Genes Dev*; 18: 2195-2224.
 430. Peterson JM, Guttridge DC (2008), *Skeletal muscle diseases, inflammation, and NF-kappaB signaling: insights and opportunities for therapeutic intervention*. *Int Rev Immunol*; 27: 375-387.
 431. Kumar A, Boriek AM (2003), *Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy*. *FASEB J*; 17: 386-396.
 432. Grounds MD, Torrissi J (2004), *Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis*. *FASEB J*; 18: 676-682.
 433. Hodgetts S, Radley H, Davies M, Grounds MD (2006), *Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice*. *Neuromuscul Disord*; 16: 591-602.
 434. Messina S, Bitto A, Aguenouz M, Minutoli L, Monici MC, Altavilla D *et al.* (2006), *Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in mdx mice*. *Exp Neurol*; 198: 234-241.
 435. Carlson CG, Samadi A, Siegel A (2005), *Chronic treatment with agents that stabilize cytosolic IkkappaB-*

- alpha* enhances survival and improves resting membrane potential in MDX muscle fibers subjected to chronic passive stretch. *Neurobiol Dis*; 20: 719-730.
436. Siegel AL, Bledsoe C, Lavin J, Gatti F, Berge J, Millman G *et al.* (2009), *Treatment with inhibitors of the NF-kappaB pathway improves whole body tension development in the mdx mouse.* *Neuromuscul Disord*; 19: 131-139.
437. Rangan GK, Wang Y, Tay YC, Harris DC (1999), *Inhibition of nuclear factor-kappaB activation reduces cortical tubulointerstitial injury in proteinuric rats.* *Kidney Int*; 56: 118-134.
438. Messina S, Bitto A, Aguenouz M, Mazzeo A, Migliorato A, Polito F *et al.* (2009), *Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: a comparison study with methylprednisolone.* *Exp Neurol*; 220: 349-358.
439. Dorchie OM, Wagner S, Vuadens O, Waldhauser K, Buetler TM, Kucera P *et al.* (2006), *Green tea extract and its major polyphenol (-)-epigallocatechin gallate improve muscle function in a mouse model for Duchenne muscular dystrophy.* *Am J Physiol Cell Physiol*; 290: C616-C625.
440. Evans NP, Call JA, Bassaganya-Riera J, Robertson JL, Grange RW (2010), *Green tea extract decreases muscle pathology and NF-kappaB immunostaining in regenerating muscle fibers of mdx mice.* *Clin Nutr*; 29: 391-398.
441. Nakae Y, Dorchie OM, Stoward PJ, Zimmermann BF, Ritter C, Ruegg UT (2012), *Quantitative evaluation of the beneficial effects in the mdx mouse of epigallocatechin gallate, an antioxidant polyphenol from green tea.* *Histochem Cell Biol*; 137: 811-827.
442. Pan Y, Chen C, Shen Y, Zhu CH, Wang G, Wang XC *et al.* (2008), *Curcumin alleviates dystrophic muscle pathology in mdx mice.* *Mol Cells*; 25: 531-537.
443. Durham WJ, Arbogast S, Gerken E, Li YP, Reid MB (2006), *Progressive nuclear factor-kappaB activation resistant to inhibition by contraction and curcumin in mdx mice.* *Muscle Nerve*; 34: 298-303.
444. Yang KY, Lin LC, Tseng TY, Wang SC, Tsai TH (2007), *Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS.* *J Chromatogr B Analyt Technol Biomed Life Sci*; 853: 183-189.
445. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C (2012), *Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases.* *Cochrane Database Syst Rev*; 3: CD007176.
446. Terrill JR, Radley-Crabb HG, Iwasaki T, Lemckert FA, Arthur PG, Grounds MD (2013), *Oxidative stress and pathology in muscular dystrophies: focus on protein thiol oxidation and dysferlinopathies.* *FEBS J*; 280: 4149-4164.
447. de Senzi Moraes PR, Ferretti R, Moraes LH, Neto HS, Marques MJ, Minatel E (2013), *N-acetylcysteine treatment reduces TNF-alpha levels and myonecrosis in diaphragm muscle of mdx mice.* *Clin Nutr*; 32: 472-475.
448. Terrill JR, Radley-Crabb HG, Grounds MD, Arthur PG (2012), *N-Acetylcysteine treatment of dystrophic mdx mice results in protein thiol modifications and inhibition of exercise induced myofibre necrosis.* *Neuromuscul Disord*; 22: 427-434.
449. Whitehead NP, Pham C, Gervasio OL, Allen DG (2008), *N-Acetylcysteine ameliorates skeletal muscle pathophysiology in mdx mice.* *J Physiol*; 586: 2003-2014.
450. Davidson ZE, Truby H (2009), *A review of nutrition in Duchenne muscular dystrophy.* *J Hum Nutr Diet*; 22: 383-393.
451. Terrill JR, Boyatzis A, Grounds MD, Arthur PG (2013), *Treatment with the cysteine precursor l-2-oxothiazolidine-4-carboxylate (OTC) implicates taurine deficiency in severity of dystrotopathology in mdx mice.* *Int J Biochem Cell Biol*; 45: 2097-2108.
452. De Luca A, Pierno S, Liantonio A, Cetrone M, Camerino C, Fraysse B *et al.* (2003), *Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-I.* *J Pharmacol Exp Ther*; 304: 453-463.
453. Cozzoli A, Rolland JF, Capogrosso RF, Sblendorio VT, Longo V, Simonetti S *et al.* (2011), *Evaluation of potential synergistic action of a combined treatment with alpha-methyl-prednisolone and taurine on the mdx mouse model of Duchenne muscular dystrophy.* *Neuropathol Appl Neurobiol*; 37: 243-256.
454. Terjung RL, Clarkson P, Eichner ER, Greenhaff PL, Hespel PJ, Israel RG *et al.* (2000), *American College of Sports Medicine roundtable. The physiological and health effects of oral creatine supplementation.* *Med Sci Sports Exerc*; 32: 706-717.
455. Pulido SM, Passaquin AC, Leijendekker WJ, Challet C, Wallimann T, Ruegg UT (1998), *Creatine supplementation improves intracellular Ca²⁺ handling and survival in mdx skeletal muscle cells.* *FEBS Lett*; 439: 357-362.
456. Passaquin AC, Renard M, Kay L, Challet C, Mokhtarian A, Wallimann T *et al.* (2002), *Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice.* *Neu-*

- romuscul Disord; 12: 174-182.
457. Louis M, Raymackers JM, Debaix H, Lebacqz J, Francaux M (2004), *Effect of creatine supplementation on skeletal muscle of mdx mice*. Muscle Nerve; 29: 687-692.
458. Pearlman JP, Fielding RA (2006), *Creatine monohydrate as a therapeutic aid in muscular dystrophy*. Nutr Rev; 64: 80-88.
459. Walter MC, Lochmuller H, Reilich P, Klopstock T, Huber R, Hartard M *et al.* (2000), *Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study*. Neurology; 54: 1848-1850.
460. Walter MC, Reilich P, Lochmuller H, Kohnen R, Schlotter B, Hautmann H *et al.* (2002), *Creatine monohydrate in myotonic dystrophy: a double-blind, placebo-controlled clinical study*. J Neurol; 249: 1717-1722.
461. Louis M, Lebacqz J, Poortmans JR, Belpaire-Dethiou MC, Devogelaer JP, Van HP *et al.* (2003), *Beneficial effects of creatine supplementation in dystrophic patients*. Muscle Nerve; 27: 604-610.
462. Tarnopolsky MA, Mahoney DJ, Vajsar J, Rodriguez C, Doherty TJ, Roy BD *et al.* (2004), *Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy*. Neurology; 62: 1771-1777.
463. Banerjee B, Sharma U, Balasubramanian K, Kalaivani M, Kalra V, Jagannathan NR (2010), *Effect of creatine monohydrate in improving cellular energetics and muscle strength in ambulatory Duchenne muscular dystrophy patients: a randomized, placebo-controlled 31P MRS study*. Magn Reson Imaging; 28: 698-707.
464. Mok E, Constantin B, Favreau F, Neveux N, Magaud C, Delwail A *et al.* (2008), *L-Glutamine administration reduces oxidized glutathione and MAP kinase signaling in dystrophic muscle of mdx mice*. Pediatr Res; 63: 268-273.
465. Hankard RG, Hammond D, Haymond MW, Darmaun D (1998), *Oral glutamine slows down whole body protein breakdown in Duchenne muscular dystrophy*. Pediatr Res; 43: 222-226.
466. Mok E, Eleouet-Da VC, Daubrosse C, Gottrand F, Rigal O, Fontan JE *et al.* (2006), *Oral glutamine and amino acid supplementation inhibit whole-body protein degradation in children with Duchenne muscular dystrophy*. Am J Clin Nutr; 83: 823-828.
467. Mok E, Letellier G, Cuisset JM, Denjean A, Gottrand F, Alberti C *et al.* (2009), *Lack of functional benefit with glutamine versus placebo in Duchenne muscular dystrophy: a randomized crossover trial*. PLoS One; 4: e5448.
468. Letellier G, Mok E, Alberti C, De LA, Gottrand F, Cuisset JM *et al.* (2013), *Effect of glutamine on glucose metabolism in children with Duchenne muscular dystrophy*. Clin Nutr; 32: 386-390.
469. Escolar DM, Buyse G, Henricson E, Leshner R, Florence J, Mayhew J *et al.* (2005), *CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy*. Ann Neurol; 58: 151-155.
470. Chaubourat E, Fossier P, Baux G, Leprince C, Israel M, de la Porte S (1999), *Nitric oxide and L-arginine cause an accumulation of utrophin at the sarcolemma: a possible compensation for dystrophin loss in Duchenne muscular dystrophy*. Neurobiol Dis; 6: 499-507.
471. Hnia K, Gayraud J, Hugon G, Ramonatox M, de la Porte S, Matecki S *et al.* (2008), *L-arginine decreases inflammation and modulates the nuclear factor-kappaB/matrix metalloproteinase cascade in mdx muscle fibers*. Am J Pathol; 172: 1509-1519.
472. Archer JD, Vargas CC, Anderson JE (2006), *Persistent and improved functional gain in mdx dystrophic mice after treatment with L-arginine and deflazacort*. FASEB J; 20: 738-740.
473. Marques MJ, Barbin IC, Taniguti AP, Oggian DS, Ferretti R, Santo NH (2010), *Myocardial fibrosis is unaltered by long-term administration of L-arginine in dystrophin deficient mdx mice: a histomorphometric analysis*. Acta Biol Hung; 61: 168-174.
474. Wehling-Henricks M, Jordan MC, Gotoh T, Grody WW, Roos KP, Tidball JG (2010), *Arginine metabolism by macrophages promotes cardiac and muscle fibrosis in mdx muscular dystrophy*. PLoS One; 5: e10763.
475. Vianello S, Yu H, Voisin V, Haddad H, He X, Foutz AS *et al.* (2013), *Arginine butyrate: a therapeutic candidate for Duchenne muscular dystrophy*. FASEB J; 27: 2256-2269.
476. Payne ET, Yasuda N, Bourgeois JM, Devries MC, Rodriguez MC, Yousuf J *et al.* (2006), *Nutritional therapy improves function and complements corticosteroid intervention in mdx mice*. Muscle Nerve; 33: 66-77.
477. Vandenburgh H, Shansky J, Benesch-Lee F, Skelly K, Spinazzola JM, Saponjian Y *et al.* (2009), *Automated drug screening with contractile muscle tissue engineered from dystrophic myoblasts*. FASEB J; 23: 3325-3334.
478. Kemaladewi DU, 't Hoen PA, ten Dijke P, van Ommen GJ, Hoogaars WM (2012), *TGF- β signaling in Duchenne muscular dystrophy*. Future Neurology; 7: 209-224.
479. Rahimi RA, Leof EB (2007), *TGF-beta signaling: a tale of two responses*. J Cell Biochem; 102: 593-608.
480. Zhang YE (2009), *Non-Smad pathways in TGF-beta signaling*. Cell Res; 19: 128-139.
481. Amthor H, Hoogaars WM (2012), *Interference with myostatin/ActRIIB signaling as a therapeutic strategy for Duchenne muscular dystrophy*. Curr Gene Ther; 12: 245-259.
482. Kemaladewi DU, de Gorter DJ, Aartsma-Rus A, van Ommen GJ, ten Dijke P, 't Hoen PA *et al.* (2012), *Cell-*

- type specific regulation of myostatin signaling*. FASEB J; 26: 1462-1472.
483. McFarlane C, Hennebry A, Thomas M, Plummer E, Ling N, Sharma M *et al.* (2008), *Myostatin signals through Pax7 to regulate satellite cell self-renewal*. Exp Cell Res; 314: 317-329.
484. Sartori R, Milan G, Patron M, Mammucari C, Blaauw B, Abraham R *et al.* (2009), *Smad2 and 3 transcription factors control muscle mass in adulthood*. Am J Physiol Cell Physiol; 296: C1248-C1257.
485. Li ZB, Kollias HD, Wagner KR (2008), *Myostatin directly regulates skeletal muscle fibrosis*. J Biol Chem; 283: 19371-19378.
486. McLennan IS, Koishi K (2002), *The transforming growth factor-betas: multifaceted regulators of the development and maintenance of skeletal muscles, motoneurons and Schwann cells*. Int J Dev Biol; 46: 559-567.
487. Kingsley DM (1994), *The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms*. Genes Dev; 8: 133-146.
488. Lee SJ, Lee YS, Zimmers TA, Soleimani A, Matzuk MM, Tsuchida K *et al.* (2010), *Regulation of muscle mass by follistatin and activins*. Mol Endocrinol; 24: 1998-2008.
489. Shi S, Hoogaars WM, de Gorter DJ, van Heiningen SH, Lin HY, Hong CC *et al.* (2011), *BMP antagonists enhance myogenic differentiation and ameliorate the dystrophic phenotype in a DMD mouse model*. Neurobiol Dis; 41: 353-360.
490. Turk R, Sterrenburg E, de Meijer EJ, van Ommen GJ, Den Dunnen JT, 't Hoen PA (2005), *Muscle regeneration in dystrophin-deficient mdx mice studied by gene expression profiling*. BMC Genomics; 6: 98.
491. Sterrenburg E, van der Wees CG, White SJ, Turk R, de Menezes RX, van Ommen GJ *et al.* (2006), *Gene expression profiling highlights defective myogenesis in DMD patients and a possible role for bone morphogenetic protein 4*. Neurobiol Dis; 23: 228-236.
492. Ono Y, Calhabeu F, Morgan JE, Katagiri T, Amthor H, Zammit PS (2011), *BMP signalling permits population expansion by preventing premature myogenic differentiation in muscle satellite cells*. Cell Death Differ; 18: 222-234.
493. Wang H, Noulet F, Edom-Vovard F, Tozer S, Le GF, Duprez D (2010), *Bmp signaling at the tips of skeletal muscles regulates the number of fetal muscle progenitors and satellite cells during development*. Dev Cell; 18: 643-654.
494. Sartori R, Schirwis E, Blaauw B, Bortolanza S, Zhao J, Enzo E *et al.* (2013), *BMP signaling controls muscle mass*. Nat Genet; 45: 1309-1318.
495. Winbanks CE, Chen JL, Qian H, Liu Y, Bernardo BC, Beyer C *et al.* (2013), *The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass*. J Cell Biol; 203: 345-357.
496. Grobet L, Martin LJ, Poncelet D, Pirottin D, Brouwers B, Riquet J *et al.* (1997), *A deletion in the bovine myostatin gene causes the double-muscling phenotype in cattle*. Nat Genet; 17: 71-74.
497. Kambadur R, Sharma M, Smith TP, Bass JJ (1997), *Mutations in myostatin (GDF8) in double-muscling Belgian Blue and Piedmontese cattle*. Genome Res; 7: 910-916.
498. McPherron AC, Lee SJ (1997), *Double muscling in cattle due to mutations in the myostatin gene*. Proc Natl Acad Sci USA; 94: 12457-12461.
499. Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W *et al.* (2004), *Myostatin mutation associated with gross muscle hypertrophy in a child*. N Engl J Med; 350: 2682-2688.
500. Shelton GD, Engvall E (2007), *Gross muscle hypertrophy in whippet dogs is caused by a mutation in the myostatin gene*. Neuromuscul Disord; 17: 721-722.
501. Clop A, Marcq F, Takeda H, Pirottin D, Tordoir X, Bibe B *et al.* (2006), *A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep*. Nat Genet; 38: 813-818.
502. McPherron AC, Lawler AM, Lee SJ (1997), *Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member*. Nature; 387: 83-90.
503. Wagner KR, Liu X, Chang X, Allen RE (2005), *Muscle regeneration in the prolonged absence of myostatin*. Proc Natl Acad Sci USA; 102: 2519-2524.
504. Mosher DS, Quignon P, Bustamante CD, Sutter NB, Mellersh CS, Parker HG *et al.* (2007), *A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs*. PLoS Genet; 3: e79.
505. Wagner KR, McPherron AC, Winik N, Lee SJ (2002), *Loss of myostatin attenuates severity of muscular dystrophy in mdx mice*. Ann Neurol; 52: 832-836.
506. Cohn RD, Liang HY, Shetty R, Abraham T, Wagner KR (2007), *Myostatin does not regulate cardiac hypertrophy or fibrosis*. Neuromuscul Disord; 17: 290-296.
507. Amthor H, Macharia R, Navarrete R, Schuelke M, Brown SC, Otto A *et al.* (2007), *Lack of myostatin results in excessive muscle growth but impaired force generation*. Proc Natl Acad Sci USA; 104: 1835-1840.
508. Welle S, Bhatt K, Pinkert CA, Tawil R, Thornton CA (2007), *Muscle growth after postdevelopmental myostatin gene knockout*. Am J Physiol Endocrinol Metab; 292: E985-E991.

509. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS *et al.* (2002), *Functional improvement of dystrophic muscle by myostatin blockade*. *Nature*; 420: 418-421.
510. Murphy KT, Ryall JG, Snell SM, Nair L, Koopman R, Krasney PA *et al.* (2010), *Antibody-directed myostatin inhibition improves diaphragm pathology in young but not adult dystrophic mdx mice*. *Am J Pathol*; 176: 2425-2434.
511. Wagner KR, Fleckenstein JL, Amato AA, Barohn RJ, Bushby K, Escolar DM *et al.* (2008), *A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy*. *Ann Neurol*; 63: 561-571.
512. Cadena SM, Tomkinson KN, Monnell TE, Spaits MS, Kumar R, Underwood KW *et al.* (2010), *Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type*. *J Appl Physiol*; 109: 635-642.
513. Carlson CG, Bruemmer K, Sesti J, Stefanski C, Curtis H, Ucran J *et al.* (2011), *Soluble activin receptor type IIB increases forward pulling tension in the mdx mouse*. *Muscle Nerve*; 43: 694-699.
514. Pistilli EE, Bogdanovich S, Goncalves MD, Ahima RS, Lachey J, Seehra J *et al.* (2011), *Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy*. *Am J Pathol*; 178: 1287-1297.
515. Attie KM, Borgstein NG, Yang Y, Condon CH, Wilson DM, Pearsall AE *et al.* (2013), *A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers*. *Muscle Nerve*; 47: 416-423.
516. Hoogaars WM, Mouisel E, Pasternack A, Hulmi JJ, Relizani K, Schuelke M *et al.* (2012), *Combined effect of AAV-U7-induced dystrophin exon skipping and soluble activin Type IIB receptor in mdx mice*. *Hum Gene Ther*; 23: 1269-1279.
517. Dumonceaux J, Marie S, Beley C, Trollet C, Vignaud A, Ferry A *et al.* (2010), *Combination of myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx mice*. *Mol Ther*; 18: 881-887.
518. Bogdanovich S, Perkins KJ, Krag TO, Whittemore LA, Khurana TS (2005), *Myostatin propeptide-mediated amelioration of dystrophic pathophysiology*. *FASEB J*; 19: 543-549.
519. Qiao C, Li J, Jiang J, Zhu X, Wang B, Li J *et al.* (2008), *Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice*. *Hum Gene Ther*; 19: 241-254.
520. Morine KJ, Bish LT, Pendrak K, Sleeper MM, Barton ER, Sweeney HL (2010), *Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice*. *PLoS One*; 5: e9176.
521. Bish LT, Sleeper MM, Forbes SC, Morine KJ, Reynolds C, Singletary GE *et al.* (2011), *Long-term systemic myostatin inhibition via liver-targeted gene transfer in golden retriever muscular dystrophy*. *Hum Gene Ther*; 22: 1499-1509.
522. Zhu J, Li Y, Lu A, Gharraibeh B, Ma J, Kobayashi T *et al.* (2011), *Follistatin improves skeletal muscle healing after injury and disease through an interaction with muscle regeneration, angiogenesis, and fibrosis*. *Am J Pathol*; 179: 915-930.
523. Lee SJ, McPherron AC (2001), *Regulation of myostatin activity and muscle growth*. *Proc Natl Acad Sci USA*; 98: 9306-9311.
524. Lee SJ (2007), *Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways*. *PLoS One*; 2: e789.
525. Haidet AM, Rizo L, Handy C, Umapathi P, Eagle A, Shilling C *et al.* (2008), *Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors*. *Proc Natl Acad Sci USA*; 105: 4318-4322.
526. Nakatani M, Takehara Y, Sugino H, Matsumoto M, Hashimoto O, Hasegawa Y *et al.* (2008), *Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice*. *FASEB J*; 22: 477-487.
527. Kota J, Handy CR, Haidet AM, Montgomery CL, Eagle A, Rodino-Klapac LR *et al.* (2009), *Follistatin gene delivery enhances muscle growth and strength in nonhuman primates*. *Sci Transl Med*; 1: 6ra15.
528. Rodino-Klapac LR, Janssen PM, Shontz KM, Canan B, Montgomery CL, Griffin D *et al.* (2013), *Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model*. *Hum Mol Genet*; 22: 4929-4937.
529. Kemaladewi DU, Hoogaars WM, van Heiningen SH, Terlouw S, de Gorter DJ, den Dunnen JT *et al.* (2011), *Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy*. *BMC Med Genomics*; 4: 36.
530. Kang JK, Malerba A, Popplewell L, Foster K, Dickson G (2011), *Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment*. *Mol Ther*; 19: 159-164.
531. Malerba A, Kang JK, McClorey G, Saleh AF, Popplewell L, Gait MJ *et al.* (2012), *Dual myostatin and dystrophin exon skipping by morpholino nucleic acid oligomers conjugated to a cell-penetrating peptide*

- is a promising therapeutic strategy for the treatment of Duchenne muscular dystrophy. *Mol Ther Nucleic Acids*; 1: e62.
532. Rodgers BD, Interlichia JP, Garikipati DK, Mamidi R, Chandra M, Nelson OL *et al.* (2009), *Myostatin represses physiological hypertrophy of the heart and excitation-contraction coupling*. *J Physiol*; 587: 4873-4886.
533. Andreetta F, Bernasconi P, Baggi F, Ferro P, Oliva L, Arnoldi E *et al.* (2006), *Immunomodulation of TGF-beta 1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: implications for antifibrotic therapy*. *J Neuroimmunol*; 175: 77-86.
534. Huebner KD, Jassal DS, Halevy O, Pines M, Anderson JE (2008), *Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone*. *Am J Physiol Heart Circ Physiol*; 294: H1550-H1561.
535. Turgeman T, Hagai Y, Huebner K, Jassal DS, Anderson JE, Genin O *et al.* (2008), *Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone*. *Neuromuscul Disord*; 18: 857-868.
536. Spector I, Zilberstein Y, Lavy A, Genin O, Barzilai-Tutsch H, Bodanovsky A *et al.* (2013), *The involvement of collagen triple helix repeat containing 1 in muscular dystrophies*. *Am J Pathol*; 182: 905-916.
537. Zanotti S, Negri T, Cappelletti C, Bernasconi P, Canioni E, Di BC *et al.* (2005), *Decorin and biglycan expression is differentially altered in several muscular dystrophies*. *Brain*; 128: 2546-2555.
538. Zanotti S, Saredi S, Ruggieri A, Fabbri M, Blasevich F, Romaggi S *et al.* (2007), *Altered extracellular matrix transcript expression and protein modulation in primary Duchenne muscular dystrophy myotubes*. *Matrix Biol*; 26: 615-624.
539. Fadic R, Mezzano V, Alvarez K, Cabrera D, Holmgren J, Brandan E (2006), *Increase in decorin and biglycan in Duchenne muscular dystrophy: role of fibroblasts as cell source of these proteoglycans in the disease*. *J Cell Mol Med*; 10: 758-769.
540. Gosselin LE, Williams JE, Deering M, Brazeau D, Koury S, Martinez DA (2004), *Localization and early time course of TGF-beta 1 mRNA expression in dystrophic muscle*. *Muscle Nerve*; 30: 645-653.
541. Li Y, Foster W, Deasy BM, Chan Y, Prisk V, Tang Y *et al.* (2004), *Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis*. *Am J Pathol*; 164: 1007-1019.
542. Li Y, Li J, Zhu J, Sun B, Branca M, Tang Y *et al.* (2007), *Decorin gene transfer promotes muscle cell differentiation and muscle regeneration*. *Mol Ther*; 15: 1616-1622.
543. Taniguti AP, Pertille A, Matsumura CY, Santo NH, Marques MJ (2011), *Prevention of muscle fibrosis and myonecrosis in mdx mice by suramin, a TGF-beta1 blocker*. *Muscle Nerve*; 43: 82-87.
544. de Oliveira Moreira D, Pereira JA, Taniguti AP, Matsumura CY, Ramos LA, Areas MA *et al.* (2013), *Suramin attenuates dystrophin-deficient cardiomyopathy in the mdx mouse model of duchenne muscular dystrophy*. *Muscle Nerve*; 48: 911-919.
545. Taniguti AP, Matsumura CY, Rodrigues-Simioni L, Santo NH, Marques MJ (2012), *Suramin affects metalloproteinase-9 activity and increases beta-dystroglycan levels in the diaphragm of the dystrophin-deficient mdx mouse*. *Muscle Nerve*; 46: 810-813.
546. Garcia-Schurmann JM, Schulze H, Haupt G, Pastor J, Allolio B, Senge T (1999), *Suramin treatment in hormone- and chemotherapy-refractory prostate cancer*. *Urology*; 53: 535-541.
547. Vidal B, Serrano AL, Tjwa M, Suelves M, Ardite E, De MR *et al.* (2008), *Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta/alternative macrophage activation pathway*. *Genes Dev*; 22: 1747-1752.
548. Mosesson MW (2005), *Fibrinogen and fibrin structure and functions*. *J Thromb Haemost*; 3: 1894-1904.
549. Vidal B, Ardite E, Suelves M, Ruiz-Bonilla V, Janue A, Flick MJ *et al.* (2012), *Amelioration of Duchenne muscular dystrophy in mdx mice by elimination of matrix-associated fibrin-driven inflammation coupled to the alphaMbeta2 leukocyte integrin receptor*. *Hum Mol Genet*; 21: 1989-2004.
550. Huang P, Zhao XS, Fields M, Ransohoff RM, Zhou L (2009), *Imatinib attenuates skeletal muscle dystrophy in mdx mice*. *FASEB J*; 23: 2539-2548.
551. Bizario JC, Cerri DG, Rodrigues LC, Oliveira GL, Nomizo A, de Araujo DD *et al.* (2009), *Imatinib mesylate ameliorates the dystrophic phenotype in exercised mdx mice*. *J Neuroimmunol*; 212: 93-101.
552. Ito T, Ogawa R, Uezumi A, Ohtani T, Watanabe Y, Tsujikawa K *et al.* (2013), *Imatinib attenuates severe mouse dystrophy and inhibits proliferation and fibrosis-marker expression in muscle mesenchymal progenitors*. *Neuromuscul Disord*; 23: 349-356.
553. Morris CA, Selsby JT, Morris LD, Pendrak K, Sweeney HL (2010), *Bowman-Birk inhibitor attenuates dystrophic pathology in mdx mice*. *J Appl Physiol*; 109: 1492-1499.
554. Cozzoli A, Nico B, Sblendorio VT, Capogrosso RF, Dinardo MM, Longo V *et al.* (2011), *Enalapril treatment discloses an early role of angiotensin II in inflammation- and oxidative stress-related muscle damage in dystrophic mdx mice*. *Pharmacol Res*; 64: 482-492.

555. Sun G, Haginoya K, Dai H, Chiba Y, Uematsu M, Hino-Fukuyo N *et al.* (2009), *Intramuscular renin-angiotensin system is activated in human muscular dystrophy*. *J Neurol Sci*; 280: 40-48.
556. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK (2002), *Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators*. *Circ Res*; 91: 406-413.
557. Wei Y, Sowers JR, Clark SE, Li W, Ferrario CM, Stump CS (2008), *Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase*. *Am J Physiol Endocrinol Metab*; 294: E345-E351.
558. Rosenkranz S (2004), *TGF-beta1 and angiotensin networking in cardiac remodeling*. *Cardiovasc Res*; 63: 423-432.
559. Yang F, Chung AC, Huang XR, Lan HY (2009), *Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways: the role of Smad3*. *Hypertension*; 54: 877-884.
560. Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, Ruperez M, Egido J, Ruiz-Ortega M (2005), *Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism*. *Circulation*; 111: 2509-2517.
561. Burks TN, Andres-Mateos E, Marx R, Mejias R, van EC, Simmers JL *et al.* (2011), *Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia*. *Sci Transl Med*; 3: 82ra37.
562. Kasper SO, Phillips EE, Castle SM, Daley BJ, Enderson BL, Karlstad MD (2011), *Blockade of the Renin-Angiotensin system improves insulin receptor signaling and insulin-stimulated skeletal muscle glucose transport in burn injury*. *Shock*; 35: 80-85.
563. Jugdutt BI (2004), *Apoptosis after reperfused myocardial infarction: Role of angiotensin II*. *Exp Clin Cardiol*; 9: 219-228.
564. Reid JL (1997), *From kinetics to dynamics: are there differences between ACE inhibitors?* *Eur Heart J*; 18 Suppl E: E14-E18.
565. Bushby K, Muntoni F, Bourke JP (2003), *107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy*. 7th-9th June 2002, Naarden, the Netherlands. *Neuromuscul Disord*; 13: 166-172.
566. Morales MG, Cabrera D, Cespedes C, Vio CP, Vazquez Y, Brandan E *et al.* (2013), *Inhibition of the angiotensin-converting enzyme decreases skeletal muscle fibrosis in dystrophic mice by a diminution in the expression and activity of connective tissue growth factor (CTGF/CCN-2)*. *Cell Tissue Res*; 353: 173-187.
567. Rafael-Fortney JA, Chimanji NS, Schill KE, Martin CD, Murray JD, Ganguly R *et al.* (2011), *Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice*. *Circulation*; 124: 582-588.
568. Krueger C, Hoffmann FM (2010), *Identification of retinoic acid in a high content screen for agents that overcome the anti-myogenic effect of TGF-beta-1*. *PLoS One*; 5: e15511.
569. Ogata H, Ishikawa Y, Ishikawa Y, Minami R (2009), *Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy*. *J Cardiol*; 53: 72-78.
570. Viollet L, Thrush PT, Flanigan KM, Mendell JR, Allen HD (2012), *Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy*. *Am J Cardiol*; 110: 98-102.
571. Jefferies JL, Eidem BW, Belmont JW, Craigen WJ, Ware SM, Fernbach SD *et al.* (2005), *Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy*. *Circulation*; 112: 2799-2804.
572. Duboc D, Meune C, Lerebours G, Devaux JY, Vaksman G, Becane HM (2005), *Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy*. *J Am Coll Cardiol*; 45: 855-857.
573. Duboc D, Meune C, Pierre B, Wahbi K, Eymard B, Toutain A *et al.* (2007), *Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up*. *Am Heart J*; 154: 596-602.
574. Glass DJ (2003), *Molecular mechanisms modulating muscle mass*. *Trends Mol Med*; 9: 344-350.
575. Zhang P, Chen X, Fan M (2007), *Signaling mechanisms involved in disuse muscle atrophy*. *Med Hypotheses*; 69: 310-321.
576. Clemmons DR (2009), *Role of IGF-I in skeletal muscle mass maintenance*. *Trends Endocrinol Metab*; 20: 349-356.
577. Florini JR, Ewton DZ, Coolican SA (1996), *Growth hormone and the insulin-like growth factor system in myogenesis*. *Endocr Rev*; 17: 481-517.
578. Gregorevic P, Plant DR, Leeding KS, Bach LA, Lynch GS (2002), *Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-I administration*. *Am J Pathol*; 161: 2263-2272.
579. Gregorevic P, Plant DR, Lynch GS (2004), *Administration of insulin-like growth factor-I improves fatigue resistance of skeletal muscles from dystrophic mdx mice*. *Muscle Nerve*; 30: 295-304.

580. Barton ER, Morris L, Musaro A, Rosenthal N, Sweeney HL (2002), *Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice*. *J Cell Biol*; 157: 137-148.
581. Schertzer JD, Ryall JG, Lynch GS (2006), *Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic mice*. *Am J Physiol Endocrinol Metab*; 291: E499-E505.
582. Schertzer JD, Gehrig SM, Ryall JG, Lynch GS (2007), *Modulation of insulin-like growth factor (IGF)-I and IGF-binding protein interactions enhances skeletal muscle regeneration and ameliorates the dystrophic pathology in mdx mice*. *Am J Pathol*; 171: 1180-1188.
583. Gehrig SM, van der Poel C, Hoefflich A, Naim T, Lynch GS, Metzger F (2012), *Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy*. *Growth Horm IGF Res*; 22: 69-75.
584. Cittadini A, Ines CL, Longobardi S, Rocco P, V, Casaburi C, Passamano L *et al.* (2003), *A preliminary randomized study of growth hormone administration in Becker and Duchenne muscular dystrophies*. *Eur Heart J*; 24: 664-672.
585. Lynch GS (2001), *Therapies for improving muscle function in neuromuscular disorders*. *Exerc Sport Sci Rev*; 29: 141-148.
586. Lynch GS, Ryall JG (2008), *Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease*. *Physiol Rev*; 88: 729-767.
587. Lynch GS, Hinkle RT, Faulkner JA (2000), *Power output of fast and slow skeletal muscles of mdx (dystrophic) and control mice after clenbuterol treatment*. *Exp Physiol*; 85: 295-299.
588. Zeman RJ, Peng H, Danon MJ, Etlinger JD (2000), *Clenbuterol reduces degeneration of exercised or aged dystrophic (mdx) muscle*. *Muscle Nerve*; 23: 521-528.
589. Lynch GS, Hinkle RT, Faulkner JA (2001), *Force and power output of diaphragm muscle strips from mdx and control mice after clenbuterol treatment*. *Neuromuscul Disord*; 11: 192-196.
590. Fowler EG, Graves MC, Wetzel GT, Spencer MJ (2004), *Pilot trial of albuterol in Duchenne and Becker muscular dystrophy*. *Neurology*; 62: 1006-1008.
591. Skura CL, Fowler EG, Wetzel GT, Graves M, Spencer MJ (2008), *Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy*. *Neurology*; 70: 137-143.
592. Kissel JT, McDermott MP, Natarajan R, Mendell JR, Pandya S, King WM *et al.* (1998), *Pilot trial of albuterol in facioscapulohumeral muscular dystrophy*. *FSH-DY Group*. *Neurology*; 50: 1402-1406.
593. Kissel JT, McDermott MP, Mendell JR, King WM, Pandya S, Griggs RC *et al.* (2001), *Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy*. *Neurology*; 57: 1434-1440.
594. Payan CA, Hogrel JY, Hammouda EH, Lacomblez L, Ollivier G, Doppler V *et al.* (2009), *Periodic salbutamol in facioscapulohumeral muscular dystrophy: a randomized controlled trial*. *Arch Phys Med Rehabil*; 90: 1094-1101.
595. Oya Y, Ogawa M, Kawai M (2001), *Therapeutic trial of beta 2-adrenergic agonist clenbuterol in muscular dystrophies*. *Rinsho Shinkeigaku*; 41: 698-700.
596. Harcourt LJ, Schertzer JD, Ryall JG, Lynch GS (2007), *Low dose formoterol administration improves muscle function in dystrophic mdx mice without increasing fatigue*. *Neuromuscul Disord*; 17: 47-55.
597. Gehrig SM, Koopman R, Naim T, Tjoarkarfa C, Lynch GS (2010), *Making fast-twitch dystrophic muscles bigger protects them from contraction injury and attenuates the dystrophic pathology*. *Am J Pathol*; 176: 29-33.
598. Leger B, Koopman R, Walrand S, Gehrig SM, Murphy KT, Lynch GS (2011), *Chronic formoterol administration reduces cardiac mitochondrial protein synthesis and oxidative capacity in mice*. *Int J Cardiol*; 146: 270-272.
599. Ryall JG, Schertzer JD, Murphy KT, Allen AM, Lynch GS (2008), *Chronic beta2-adrenoceptor stimulation impairs cardiac relaxation via reduced SR Ca²⁺-ATPase protein and activity*. *Am J Physiol Heart Circ Physiol*; 294: H2587-H2595.
600. Orr R, Fiatarone SM (2004), *The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety*. *Drugs*; 64: 725-750.
601. Fenichel G, Pestronk A, Florence J, Robison V, Hemelt V (1997), *A beneficial effect of oxandrolone in the treatment of Duchenne muscular dystrophy: a pilot study*. *Neurology*; 48: 1225-1226.
602. Fenichel GM, Griggs RC, Kissel J, Kramer TI, Mendell JR, Moxley RT *et al.* (2001), *A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy*. *Neurology*; 56: 1075-1079.
603. Balagopal P, Olney R, Darmaun D, Mougey E, Dokler M, Sieck G *et al.* (2006), *Oxandrolone enhances skeletal muscle myosin synthesis and alters global gene expression profile in Duchenne muscular dystrophy*. *Am J Physiol Endocrinol Metab*; 290: E530-E539.
604. Krahn MJ, Anderson JE (1994), *Anabolic steroid treatment increases myofiber damage in mdx mouse*

- muscular dystrophy*. *J Neurol Sci*; 125: 138-146.
605. Guidance for Industry (2005), <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078932.pdf>.
606. Cozzoli A, Capogrosso RF, Sblendorio VT, Dinardo MM, Jagerschmidt C, Namour F *et al.* (2013), *GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy*. *Pharmacol Res*; 72: 9-24.
607. Dorchies OM, Reutenauer-Patte J, Dahmane E, Ismail HM, Petermann O, Vuadens O *et al.* (2013), *The anticancer drug tamoxifen counteracts the pathology in a mouse model of duchenne muscular dystrophy*. *Am J Pathol*; 182: 485-504.
608. Selsby J, Pendrak K, Zadel M, Tian Z, Pham J, Carver T *et al.* (2010), *Leupeptin-based inhibitors do not improve the mdx phenotype*. *Am J Physiol Regul Integr Comp Physiol*; 299: R1192-R1201.
609. Consalvi S, Saccone V, Giordani L, Minetti G, Mozzetta C, Puri PL (2011), *Histone deacetylase inhibitors in the treatment of muscular dystrophies: epigenetic drugs for genetic diseases*. *Mol Med*; 17: 457-465.
610. Minetti GC, Colussi C, Adami R, Serra C, Mozzetta C, Parente V *et al.* (2006), *Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors*. *Nat Med*; 12: 1147-1150.
611. Consalvi S, Mozzetta C, Bettica P, Germani M, Fiorentini F, Del BF *et al.* (2013), *Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat*. *Mol Med*; 19: 79-87.
612. Burkin DJ, Wallace GQ, Nicol KJ, Kaufman DJ, Kaufman SJ (2001), *Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice*. *J Cell Biol*; 152: 1207-1218.
613. Gurpur PB, Liu J, Burkin DJ, Kaufman SJ (2009), *Valproic acid activates the PI3K/Akt/mTOR pathway in muscle and ameliorates pathology in a mouse model of Duchenne muscular dystrophy*. *Am J Pathol*; 174: 999-1008.
614. Rommel C, Clarke BA, Zimmermann S, Nunez L, Rossman R, Reid K *et al.* (1999), *Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt*. *Science*; 286: 1738-1741.
615. Grounds MD (2008), *Two-tiered hypotheses for Duchenne muscular dystrophy*. *Cell Mol Life Sci*; 65: 1621-1625.
616. Deconinck N, Dan B (2007), *Pathophysiology of duchenne muscular dystrophy: current hypotheses*. *Pediatr Neurol*; 36: 1-7.
617. Allen DG, Gervasio OL, Yeung EW, Whitehead NP (2010), *Calcium and the damage pathways in muscular dystrophy*. *Can J Physiol Pharmacol*; 88: 83-91.
618. Iwata Y, Katanosaka Y, Arai Y, Shigekawa M, Wakabayashi S (2009), *Dominant-negative inhibition of Ca²⁺ influx via TRPV2 ameliorates muscular dystrophy in animal models*. *Hum Mol Genet*; 18: 824-834.
619. Harissh R, Chatelier A, Magaud C, Deliot N, Constantin B (2013), *Involvement of TRPV2 and SOCE in calcium influx disorder in DMD primary human myotubes with a specific contribution of alpha1-syntrophin and PLC/PKC in SOCE regulation*. *Am J Physiol Cell Physiol*; 304: C881-C894.
620. Gehrig SM, van der Poel C, Sayer TA, Schertzer JD, Henstridge DC, Church JE *et al.* (2012), *Hsp72 preserves muscle function and slows progression of severe muscular dystrophy*. *Nature*; 484: 394-398.
621. Millay DP, Sargent MA, Osinska H, Baines CP, Barton ER, Vuagniaux G *et al.* (2008), *Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy*. *Nat Med*; 14: 442-447.
622. Chen YW, Zhao P, Borup R, Hoffman EP (2000), *Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology*. *J Cell Biol*; 151: 1321-1336.
623. Berman B, Duncan MR (1989), *Pentoxifylline inhibits normal human dermal fibroblast in vitro proliferation, collagen, glycosaminoglycan, and fibronectin production, and increases collagenase activity*. *J Invest Dermatol*; 92: 605-610.
624. Berman B, Wietzerbin J, Sanceau J, Merlin G, Duncan MR (1992), *Pentoxifylline inhibits certain constitutive and tumor necrosis factor-alpha-induced activities of human normal dermal fibroblasts*. *J Invest Dermatol*; 98: 706-712.
625. Rolland JF, De LA, Burdi R, Andreetta F, Confalonieri P, Conte CD (2006), *Overactivity of exercise-sensitive cation channels and their impaired modulation by IGF-1 in mdx native muscle fibers: beneficial effect of pentoxifylline*. *Neurobiol Dis*; 24: 466-474.
626. Gosselin LE, Williams JE (2006), *Pentoxifylline fails to attenuate fibrosis in dystrophic (mdx) diaphragm muscle*. *Muscle Nerve*; 33: 820-823.
627. Zimmerman A, Clemens PR, Tesi-Rocha C, Connolly A, Iannaccone ST, Kuntz N *et al.* (2011), *Liquid formulation of pentoxifylline is a poorly tolerated treatment for duchenne dystrophy*. *Muscle Nerve*; 44: 170-173.
628. Escolar DM, Zimmerman A, Bertorini T, Clemens PR, Connolly AM, Mesa L *et al.* (2012), *Pentoxifylline*

- as a rescue treatment for DMD: a randomized double-blind clinical trial. *Neurology*; 78: 904-913.
629. Matsumura CY, Pertille A, Albuquerque TC, Santo NH, Marques MJ (2009), *Diltiazem and verapamil protect dystrophin-deficient muscle fibers of MDX mice from degeneration: a potential role in calcium buffering and sarcolemmal stability*. *Muscle Nerve*; 39: 167-176.
630. Pernice W, Beckmann R, Ketelsen UP, Frey M, Schmidt-Redemann B, Haap KP *et al.* (1988), *A double-blind placebo controlled trial of diltiazem in Duchenne dystrophy*. *Klin Wochenschr*; 66: 565-570.
631. Bertorini TE, Palmieri GM, Griffin JW, Igarashi M, McGee J, Brown R *et al.* (1988), *Effect of chronic treatment with the calcium antagonist diltiazem in Duchenne muscular dystrophy*. *Neurology*; 38: 609-613.
632. Phillips MF, Quinlivan R (2008), *Calcium antagonists for Duchenne muscular dystrophy*. *Cochrane Database Syst Rev*; CD004571.
633. Gentil C, Leturcq F, Ben YR, Kaplan JC, Laforet P, Penisson-Besnier I *et al.* (2012), *Variable phenotype of del45-55 Becker patients correlated with nNOSmu mislocalization and RYR1 hypernitrosylation*. *Hum Mol Genet*; 21: 3449-3460.
634. Weigl L, Zidar A, Gscheidlinger R, Karel A, Hohenegger M (2003), *Store operated Ca²⁺ influx by selective depletion of ryanodine sensitive Ca²⁺ pools in primary human skeletal muscle cells*. *Naunyn Schmiedeberg Arch Pharmacol*; 367: 353-363.
635. Richard I, Broux O, Allamand V, Fougerousse F, Chiannilkulchai N, Bourg N *et al.* (1995), *Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A*. *Cell*; 81: 27-40.
636. Briguet A, Erb M, Courdier-Fruh I, Barzaghi P, Santos G, Herzner H *et al.* (2008), *Effect of calpain and proteasome inhibition on Ca²⁺-dependent proteolysis and muscle histopathology in the mdx mouse*. *FASEB J*; 22: 4190-4200.
637. Spencer MJ, Mellgren RL (2002), *Overexpression of a calpastatin transgene in mdx muscle reduces dystrophic pathology*. *Hum Mol Genet*; 11: 2645-2655.
638. Badalamente MA, Stracher A (2000), *Delay of muscle degeneration and necrosis in mdx mice by calpain inhibition*. *Muscle Nerve*; 23: 106-111.
639. Childers MK, Bogan JR, Bogan DJ, Greiner H, Holder M, Grange RW *et al.* (2011), *Chronic administration of a leupeptin-derived calpain inhibitor fails to ameliorate severe muscle pathology in a canine model of duchenne muscular dystrophy*. *Front Pharmacol*; 2: 89.
640. Burdi R, Didonna MP, Pignol B, Nico B, Mangieri D, Rolland JF *et al.* (2006), *First evaluation of the potential effectiveness in muscular dystrophy of a novel chimeric compound, BN 82270, acting as calpain-inhibitor and anti-oxidant*. *Neuromuscul Disord*; 16: 237-248.
641. von Moers A, Zwirner A, Reinhold A, Bruckmann O, van LF, Stoltenburg-Didingen G *et al.* (2005), *Increased mRNA expression of tissue inhibitors of metalloproteinase-1 and -2 in Duchenne muscular dystrophy*. *Acta Neuropathol*; 109: 285-293.
642. Nadarajah VD, van PM, Chaouch A, Garrood P, Straub V, Lochmuller H *et al.* (2011), *Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD)*. *Neuromuscul Disord*; 21: 569-578.
643. Kumar A, Bhatnagar S, Kumar A (2010), *Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice*. *Am J Pathol*; 177: 248-260.
644. Li H, Mittal A, Makonchuk DY, Bhatnagar S, Kumar A (2009), *Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy*. *Hum Mol Genet*; 18: 2584-2598.
645. Miyazaki D, Nakamura A, Fukushima K, Yoshida K, Takeda S, Ikeda S (2011), *Matrix metalloproteinase-2 ablation in dystrophin-deficient mdx muscles reduces angiogenesis resulting in impaired growth of regenerated muscle fibers*. *Hum Mol Genet*; 20: 1787-1799.
646. De Palma C, Morisi F, Cheli S, Pambianco S, Cappello V, Vezzoli M *et al.* (2012), *Autophagy as a new therapeutic target in Duchenne muscular dystrophy*. *Cell Death Dis*; 3: e418.
647. Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Del PP *et al.* (2007), *FoxO3 controls autophagy in skeletal muscle in vivo*. *Cell Metab*; 6: 458-471.
648. Mammucari C, Schiaffino S, Sandri M (2008), *Downstream of Akt: FoxO3 and mTOR in the regulation of autophagy in skeletal muscle*. *Autophagy*; 4: 524-526.
649. Pauly M, Daussin F, Burelle Y, Li T, Godin R, Fauconnier J *et al.* (2012), *AMPK activation stimulates autophagy and ameliorates muscular dystrophy in the mdx mouse diaphragm*. *Am J Pathol*; 181: 583-592.
650. Chatterjee S, Moeller C, Shah N, Bolorunduro O, Lichstein E, Moskovits N *et al.* (2012), *Eplerenone is not superior to older and less expensive aldosterone antagonists*. *Am J Med*; 125: 817-825.
651. Miller AB (2007), *Aldosterone antagonism in heart failure*. *Vasc Health Risk Manag*; 3: 605-609.
652. Weber MA, Nagel AM, Wolf MB, Jurkat-Rott K, Kauczor HU, Semmler W *et al.* (2012), *Permanent muscular sodium overload and persistent muscle edema in Duchenne muscular dystrophy: a possible contributor of progressive muscle degeneration*. *J Neurol*; 259: 2385-2392.

653. Lehmann-Horn F, Weber MA, Nagel AM, Meinck HM, Breitenbach S, Scharrer J *et al.* (2012), *Rationale for treating oedema in Duchenne muscular dystrophy with eplerenone*. *Acta Myol*; 31: 31-39.
654. Frishman WH (1998), *Carvedilol*. *N Engl J Med*; 339: 1759-1765.
655. Saito T, Matsumura T, Miyai I, Nozaki S, Shinno S (2001), *Carvedilol effectiveness for left ventricular-insufficient patients with Duchenne muscular dystrophy*. *Rinsho Shinkeigaku*; 41: 691-694.
656. Matsumura T, Tamura T, Kuru S, Kikuchi Y, Kawai M (2010), *Carvedilol can prevent cardiac events in Duchenne muscular dystrophy*. *Intern Med*; 49: 1357-1363.
657. Kajimoto H, Ishigaki K, Okumura K, Tomimatsu H, Nakazawa M, Saito K *et al.* (2006), *Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy*. *Circ J*; 70: 991-994.
658. <http://www.treat-nmd.eu>
659. Willmann R, De LA, Benatar M, Grounds M, Dubach J, Raymackers JM *et al.* (2012), *Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice*. *Neuromuscul Disord*; 22: 43-49.
660. Mendell JR, Shilling C, Leslie ND, Flanigan KM, al-Dahhak R, Gastier-Foster J *et al.* (2012), *Evidence-based path to newborn screening for Duchenne muscular dystrophy*. *Ann Neurol*; 71: 304-313.
661. Aartsma-Rus A (2010), *Antisense-mediated modulation of splicing: therapeutic implications for Duchenne muscular dystrophy*. *RNA Biol*; 7: 453-461.
662. Tennyson CN, Shi Q, Worton RG (1996), *Stability of the human dystrophin transcript in muscle*. *Nucleic Acids Res*; 24: 3059-3064.
663. Spitali P, Heemskerk H, Vossen RH, Ferlini A, den Dunnen JT, 't Hoen PA *et al.* (2010), *Accurate quantification of dystrophin mRNA and exon skipping levels in duchenne muscular dystrophy*. *Lab Invest*; 90: 1396-1402.
664. Yu RZ, Baker B, Chappell A, Geary RS, Cheung E, Levin AA (2002), *Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma*. *Anal Biochem*; 304: 19-25.
665. R Development Core Team (2009), *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing.
666. Bates D, Maechler M (2010), *lme4: Linear mixed-effects models using S4 classes*. R package version 0.999375-35.
667. Spitali P, Aartsma-Rus A (2012), *Splice modulating therapies for human disease*. *Cell*; 148: 1085-1088.
668. Brown DA, Kang SH, Gryaznov SM, DeDionisio L, Heidenreich O, Sullivan S *et al.* (1994), *Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding*. *J Biol Chem*; 269: 26801-26805.
669. Yu RZ, Kim TW, Hong A, Watanabe TA, Gaus HJ, Geary RS (2007), *Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100*. *Drug Metab Dispos*; 35: 460-468.
670. Blake DJ, Weir A, Newey SE, Davies KE (2002), *Function and genetics of dystrophin and dystrophin-related proteins in muscle*. *Physiol Rev*; 82: 291-329.
671. Torres LF, Duchon LW (1987), *The mutant mdx: inherited myopathy in the mouse. Morphological studies of nerves, muscles and end-plates*. *Brain*; 110 (Pt 2): 269-299.
672. Banks GB, Chamberlain JS (2008), *The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies*. *Curr Top Dev Biol*; 84: 431-453.
673. Verhaart IE, Aartsma-Rus A (2012), *Gene therapy for Duchenne muscular dystrophy*. *Curr Opin Neurol*; 25: 588-596.
674. Spitali P, van den Bergen JC, Verhaart IE, Wokke B, Janson AA, van den Eijnde R *et al.* (2013), *DMD transcript imbalance determines dystrophin levels*. *FASEB J*; 27: 4909-4916.
675. Yazaki M, Yoshida K, Nakamura A, Koyama J, Nanba T, Ohori N *et al.* (1999), *Clinical characteristics of aged Becker muscular dystrophy patients with onset after 30 years*. *Eur Neurol*; 42: 145-149.
676. Aartsma-Rus A (2012), *Overview on AON design*. *Methods Mol Biol*; 867: 117-129.
677. Yin H, Moulton HM, Seow Y, Boyd C, Boutilier J, Iverson P *et al.* (2008), *Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function*. *Hum Mol Genet*; 17: 3909-3918.
678. Elion GB (1989), *The purine path to chemotherapy*. *Science*; 244: 41-47.
679. Zhu CH, Mouly V, Cooper RN, Mamchaoui K, Bigot A, Shay JW *et al.* (2007), *Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclin-dependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies*. *Aging Cell*; 6: 515-523.
680. Amantana A, Iversen PL (2005), *Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers*. *Curr Opin Pharmacol*; 5: 550-555.
681. Swann PF, Waters TR, Moulton DC, Xu YZ, Zheng Q, Edwards M *et al.* (1996), *Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine*. *Science*; 273: 1109-1111.

682. Waters TR, Swann PF (1997), *Cytotoxic mechanism of 6-thioguanine: hMutSalpha, the human mismatch binding heterodimer, binds to DNA containing S6-methylthioguanine*. *Biochemistry*; 36: 2501-2506.
683. Somerville L, Krynetski EY, Krynetskaia NF, Beger RD, Zhang W, Marhefka CA *et al.* (2003), *Structure and dynamics of thioguanine-modified duplex DNA*. *J Biol Chem*; 278: 1005-1011.
684. Ling YH, Chan JY, Beattie KL, Nelson JA (1992), *Consequences of 6-thioguanine incorporation into DNA on polymerase, ligase, and endonuclease reactions*. *Mol Pharmacol*; 42: 802-807.
685. Marathias VM, Sawicki MJ, Bolton PH (1999), *6-Thioguanine alters the structure and stability of duplex DNA and inhibits quadruplex DNA formation*. *Nucleic Acids Res*; 27: 2860-2867.
686. Uribe-Luna S, Quintana-Hau JD, Maldonado-Rodriguez R, Espinosa-Lara M, Beattie KL, Farquhar D *et al.* (1997), *Mutagenic consequences of the incorporation of 6-thioguanine into DNA*. *Biochem Pharmacol*; 54: 419-424.
687. Hann IM, Stevens RF, Goldstone AH, Rees JK, Wheatley K, Gray RG *et al.* (1997), *Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council*. *Blood*; 89: 2311-2318.
688. Preisler H, Davis RB, Kirshner J, Dupre E, Richards F, III, Hoagland HC *et al.* (1987), *Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study*. *Blood*; 69: 1441-1449.
689. Pinkel D (1993), *Intravenous mercaptopurine: life begins at 40*. *J Clin Oncol*; 11: 1826-1831.
690. Sheu CJ, Moreland FM (1983), *Detection of dominant lethal mutation in mice after repeated low-dose administration of 6-mercaptopurine*. *Drug Chem Toxicol*; 6: 83-92.
691. Koenig M, Monaco AP, Kunkel LM (1988), *The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein*. *Cell*; 53: 219-228.
692. Blake DJ, Weir A, Newey SE, Davies KE (2002), *Function and genetics of dystrophin and dystrophin-related proteins in muscle*. *Physiol Rev*; 82: 291-329.
693. Alexakis C, Partridge T, Bou-Gharios G (2007), *Implication of the satellite cell in dystrophic muscle fibrosis: a self-perpetuating mechanism of collagen overproduction*. *Am J Physiol Cell Physiol*; 293: C661-C669.
694. Mezzano V, Cabrera D, Vial C, Brandan E (2007), *Constitutively activated dystrophic muscle fibroblasts show a paradoxical response to TGF-beta and CTGF/CCN2*. *J Cell Commun Signal*; 1: 205-217.
695. Desguerre I, Mayer M, Leturcq F, Barbet JP, Gherardi RK, Christov C (2009), *Endomysial fibrosis in Duchenne muscular dystrophy: a marker of poor outcome associated with macrophage alternative activation*. *J Neuropathol Exp Neurol*; 68: 762-773.
696. Chen YW, Nagaraju K, Bakay M, McIntyre O, Rawat R, Shi R *et al.* (2005), *Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy*. *Neurology*; 65: 826-834.
697. Aartsma-Rus A, van Ommen GJ (2007), *Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications*. *RNA*; 13: 1609-1624.
698. Payne ET, Yasuda N, Bourgeois JM, Devries MC, Rodriguez MC, Yousuf J *et al.* (2006), *Nutritional therapy improves function and complements corticosteroid intervention in mdx mice*. *Muscle Nerve*; 33: 66-77.
699. Anderson LV, Davison K (1999), *Multiplex Western blotting system for the analysis of muscular dystrophy proteins*. *Am J Pathol*; 154: 1017-1022.
700. Ruijter JM, Ramakers C, Hoogaars WM, Karlen Y, Bakker O, van den Hoff MJ *et al.* (2009), *Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data*. *Nucleic Acids Res*; 37: e45.
701. Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP *et al.* (1989), *Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy*. *N Engl J Med*; 320: 1592-1597.
702. Tanabe Y, Esaki K, Nomura T (1986), *Skeletal muscle pathology in X chromosome-linked muscular dystrophy (mdx) mouse*. *Acta Neuropathol*; 69: 91-95.
703. Doran P, Wilton SD, Fletcher S, Ohlendieck K (2009), *Proteomic profiling of antisense-induced exon skipping reveals reversal of pathobiochemical abnormalities in dystrophic mdx diaphragm*. *Proteomics*; 9: 671-685.
704. Yao W, Cheng Z, Pham A, Busse C, Zimmermann EA, Ritchie RO *et al.* (2008), *Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization*. *Arthritis Rheum*; 58: 3485-3497.
705. Keeling RM, Golumbek PT, Streif EM, Connolly AM (2007), *Weekly oral prednisolone improves survival and strength in male mdx mice*. *Muscle Nerve*; 35: 43-48.
706. 't Hoen PA, van der Wees CG, Aartsma-Rus A, Turk R, Goyenvalle A, Danos O *et al.* (2006), *Gene expression profiling to monitor therapeutic and adverse effects of antisense therapies for Duchenne muscular dystrophy*. *Pharmacogenomics*; 7: 281-297.
707. Spurney CF, Knoblach S, Pistilli EE, Nagaraju K, Martin GR, Hoffman EP (2008), *Dystrophin-deficient cardiomyopathy in mouse: expression of Nox4 and Lox are associated with fibrosis and altered functional*

- parameters in the heart*. Neuromuscul Disord; 18: 371-381.
708. Jin Y, Murakami N, Saito Y, Goto Y, Koishi K, Nonaka I (2000), *Expression of MyoD and myogenin in dystrophic mice, mdx and dy, during regeneration*. Acta Neuropathol; 99: 619-627.
709. te Pas MF, de Jong PR, Verburg FJ (2000), *Glucocorticoid inhibition of C2C12 proliferation rate and differentiation capacity in relation to mRNA levels of the MRF gene family*. Mol Biol Rep; 27: 87-98.
710. van Putten M, Aartsma-Rus A (2011), *Opportunities and challenges for the development of antisense treatment in neuromuscular disorders*. Expert Opin Biol Ther; 11: 1025-1037.
711. Almon RR, Dubois DC, Jusko WJ (2007), *A microarray analysis of the temporal response of liver to methylprednisolone: a comparative analysis of two dosing regimens*. Endocrinology; 148: 2209-2225.
712. Marotta M, Sarria Y, Ruiz-Roig C, Munell F, Roig-Quilis M (2007), *Laser microdissection-based expression analysis of key genes involved in muscle regeneration in mdx mice*. Neuromuscul Disord; 17: 707-718.
713. Cacchiarelli D, Incitti T, Martone J, Cesana M, Cazzella V, Santini T et al. (2011), *miR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy*. EMBO Rep; 12: 136-141.
714. Paul M, Poyan MA, Kreutz R (2006), *Physiology of local renin-angiotensin systems*. Physiol Rev; 86: 747-803.
715. Zhou L, Porter JD, Cheng G, Gong B, Hatala DA, Merriam AP et al. (2006), *Temporal and spatial mRNA expression patterns of TGF-beta1, 2, 3 and TbetaRI, II, III in skeletal muscles of mdx mice*. Neuromuscul Disord; 16: 32-38.
716. Bernasconi P, Torchiana E, Confalonieri P, Brugnani R, Barresi R, Mora M et al. (1995), *Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine*. J Clin Invest; 96: 1137-1144.
717. van Putten M, de Winter C, van Roon-Mom W, van Ommen GJ, 't Hoen PA, Aartsma-Rus A (2010), *A 3 months mild functional test regime does not affect disease parameters in young mdx mice*. Neuromuscul Disord; 20: 273-280.

